Summary
Necrosis of macrophages in the granuloma, the hallmark immunological structure of tuberculosis, is a major pathogenic event that increases host susceptibility. Through a zebrafish forward genetic screen, we identified the mTOR kinase, a master regulator of metabolism, as an early host resistance factor in tuberculosis. We found that mTOR complex 1 protects macrophages from mycobacterium-induced death by enabling infection-induced increases in mitochondrial energy metabolism fueled by glycolysis. These metabolic adaptations are required to prevent mitochondrial damage and death caused by the secreted mycobacterial virulence determinant ESAT-6. Thus, the host can effectively counter this early critical mycobacterial virulence mechanism simply by regulating energy metabolism, thereby allowing pathogen-specific immune mechanisms time to develop. Our findings may explain why Mycobacterium tuberculosis, albeit humanity’s most lethal pathogen, is successful in only a minority of infected individuals.
Keywords: tuberculosis, mTOR, ESAT-6 mitotoxicity, mitochondrial metabolism, oxidative phosphorylation, zebrafish TB model, Mycobacterium marinum, Mycobacterium tuberculosis, macrophage death, granuloma necrosis
Graphical abstract
Highlights
-
•
mTOR deficiency confers susceptibility to mycobacterial infection
-
•
mTOR deficiency sensitizes macrophages to mycobacterium-induced cytotoxicity
-
•
Mycobacterial ESAT-6-induced mitochondrial damage kills mTOR-deficient macrophages
-
•
mTOR-supported OXPHOS protects from ESAT-6-mediated virulence
mTOR is an early host resistance factor in tuberculosis that prevents mitochondrial damage and protects macrophages by increasing mitochondrial energy metabolism fueled by glycolysis.
Introduction
Mycobacterium tuberculosis (Mtb) induces the formation of granulomas, organized structures comprised of macrophages within which mycobacteria reside, and accessory cells (Pagán and Ramakrishnan, 2014, 2018; Ramakrishnan, 2012). The granuloma represents a key host-pathogen battleground that determines the outcome of tuberculosis (TB) infection (Pagán and Ramakrishnan, 2014; Ramakrishnan, 2012). In most individuals, the granuloma successfully clears Mtb infection, often leaving a residual, sterile, fibrotic structure as a stamp of past infection (Behr et al., 2019; Canetti et al., 1972; Feldman and Baggenstoss, 1938; Opie and Aronson, 1927; Terplan, 1951). In contrast, in the minority of people who go on to develop TB, the granuloma often becomes a mycobacterium-beneficial structure that promotes bacterial expansion and dissemination (Pagán and Ramakrishnan, 2014; Ramakrishnan, 2012). Granuloma necrosis is a pivotal pathogenic event because it delivers macrophage-resident mycobacteria into the growth-enhancing extracellular milieu (Pagán and Ramakrishnan, 2014; Ramakrishnan, 2012; Russell, 2007). Necrosis of lung granulomas with their attendant rupture into the airways also facilitates transmission, sustaining the global TB burden and promoting Mtb’s evolutionary survival (Ong et al., 2014; Ramakrishnan, 2012). Mtb’s exploitation of the granuloma begins in the innate stage of the response, enabling Mtb to gain a foothold in the host (Cambier et al., 2014a; Pagán and Ramakrishnan, 2014; Ramakrishnan, 2012). Thus, innate immune dysfunctions that facilitate this exploitation can lead to susceptibility (Cambier et al., 2014a; Pagán and Ramakrishnan, 2014; Ramakrishnan, 2012).
Zebrafish infected with Mycobacterium marinum (Mm), a close relative of Mtb, develop TB-like disease with necrotic granulomas (Cosma et al., 2003; Swaim et al., 2006). Mm-infected zebrafish larvae in which adaptive immunity has not yet developed also form organized granulomas that undergo necrosis (Davis et al., 2002). Thus, the zebrafish larva offers the opportunity to dissect the contribution of innate immunity in tuberculous granuloma formation and necrosis (Davis et al., 2002; Davis and Ramakrishnan, 2009; Ramakrishnan, 2013, 2020). The larva’s optical transparency and genetic tractability enables the detailed, sequential monitoring by intravital microscopy of the steps of infection, the contribution of host and pathogen determinants to them, and the consequences to outcome (Ramakrishnan, 2013). The use of unbiased genetic screens and candidate gene approaches in zebrafish larvae has shed light on granuloma biology (Ramakrishnan, 2013). Hypersusceptible zebrafish mutants displaying accelerated granuloma necrosis have identified innate immune host determinants that protect against necrosis and that are relevant to human TB (Berg et al., 2016; Clay et al., 2008; Pagán et al., 2015; Roca and Ramakrishnan, 2013; Roca et al., 2019, 2022; Tobin et al., 2010, 2012; Whitworth et al., 2021a, 2021b).
Here, we report on insights into TB pathogenesis and resistance gained from the genetic mapping and characterization of a loss-of-function mutant in mechanistic target of rapamycin (mTOR) that exhibits rapid granuloma necrosis. The mTOR pathway integrates environmental signals emanating from diverse nutrient-sensing and growth factor receptor pathways to regulate biosynthetic and metabolic processes vital for cellular development, growth, survival, and function (Liu and Sabatini, 2020). Iterative experimental approaches in the zebrafish and in human macrophages uncover the mitotoxic function of mycobacterial ESAT-6 and show that mTOR-facilitated mitochondrial metabolism serves as a highly effective innate “counter virulence” factor in TB by exerting a mitoprotective effect against this critical mycobacterial virulence factor.
Results
mTORC1 deficiency confers susceptibility to Mm infection in zebrafish
The zebrafish mutant fh178, identified in a forward genetic screen (Tobin et al., 2010), was hypersusceptible to Mm, with larvae exhibiting increased bacterial burdens relative to wild-type (WT) and heterozygote siblings following infection into the caudal vein (cv) (Figures 1A–1C). By 4 days post-infection (dpi), fh178 mutant granulomas had depleted their macrophages and the released mycobacteria were growing extracellularly in rope-like cords (Pagán et al., 2015; Tobin et al., 2010; Figures 1D and 1E). Mycobacterial cording, a sensitive and specific surrogate for macrophage depletion, is a readily quantifiable, binary phenotype for mapping mutants rendered hypersusceptible by granuloma necrosis (Berg et al., 2016; Tobin et al., 2010). Using polymorphic markers and the mycobacterial cording phenotype, we mapped the fh178 mutation to a nonsense mutation in exon 24 of the mtor gene (see STAR Methods). We confirmed that genetic disruption of mtor was the cause of fh178 hypersusceptibility by showing that animals with a nonsense mutation in exon 19 (mtorsa16755) (Kettleborough et al., 2013) also exhibited hypersusceptibility with cording, as did compound fh178/sa16755 heterozygotes (Figures 1F and 1G).
mTOR is a kinase that functions in two distinct complexes, mTORC1 and mTORC2, that require the adaptors Raptor and Rictor, respectively (Liu and Sabatini, 2020). Animals with nonsense alleles of rptor, the gene encoding Raptor, showed similar cording to the mtor mutants, whereas those with nonsense alleles of Rictor did not (Figures 1H and 1I). Inhibition of mTOR or mTORC1 with torin1 or rapamycin, respectively (Benjamin et al., 2011), recapitulated genetic mTOR/mTORC1 deficiency with increased cording (Figure 1J). Thus, mTORC1 deficiency confers susceptibility to mycobacterial infection, linked to early granuloma breakdown. Because zebrafish larvae have not yet developed adaptive immunity, this reflects innate resistance conferred by mTOR.
mTOR deficiency accelerates death of mycobacterium--infected macrophages
At 4 dpi, WT animals had granulomas with sparse intracellular bacteria; in contrast, mTOR-deficient animals had clusters of extracellular bacteria in shapes similar to WT granulomas, suggesting that they had been in granulomas that had broken down due to macrophage death (Figure 1D, compare top and bottom). To detail the kinetics of macrophage death, we infected zebrafish larvae in the hindbrain ventricle (hbv), an acellular compartment ideal for monitoring early granuloma formation (Davis and Ramakrishnan, 2009). Animals rendered mTOR-deficient by rapamycin treatment formed granulomas similar to WT by 2 dpi, but their macrophages died by 3 dpi, leaving clumps of extracellular bacteria (Figure 2A).
We hypothesized that mTORC1 deficiency might cause granuloma breakdown through its impairment of myelopoiesis (Karmaus et al., 2017; Lee et al., 2017). The paucity of available macrophages to replenish the growing granuloma could cause its breakdown, similar to the case of myeloid growth factor colony stimulating factor-1 receptor (CSF-1R) deficiency (Pagán et al., 2015). Supporting this possibility, mTORC1 promotes myelopoiesis through CSF-1R (Karmaus et al., 2017). However, even though mTORC1-deficient animals had more macrophages at baseline than CSF-1R-deficient animals, their granulomas broke down sooner (2–4 days versus 5–7 for CSF-1R mutants) (Figure 2B; Pagán et al., 2015), suggesting that mTOR deficiency induces death of infected granuloma macrophages independently of reducing basal macrophage supply. In support of this, rapamycin treatment after formation of granulomas caused their rapid breakdown (Figure 2C). For further confirmation, we used time-lapse microscopy to capture in real-time the death of infected macrophages. If mTOR-deficient granulomas are breaking down due to reduced macrophage replenishment, then dying mTOR mutant macrophages should have bacterial burdens similar to or greater than WT. To assess bacterial burdens in dying macrophages, we used blue fluorescent Mm to infect mTOR-deficient animals and their WT siblings, which had red fluorescent macrophage membranes. All animals were also transgenic for a ubiquitously expressed secreted annexin V tagged with yellow fluorescent protein (Tg(ubb:secA5-YFP)), which accumulates on the surface of cells undergoing apoptosis and other modes of regulated cell death (Bendall and Green, 2014). We monitored macrophage death by the appearance of annexin V-YFP labeling of the plasma membrane and membrane blebs followed by the loss of tdTomato fluorescence reflecting plasma membrane disintegration (Figure 2D; Video S1). In 2 dpi animals, over a 4.5-h imaging period that captured similar numbers of infected macrophages in mTOR-deficient and WT siblings, 6-fold more mTOR-deficient macrophages died (Figures 2E and 2F; Video S2). Importantly, mTOR-deficient macrophages died with lower bacterial burdens than WT (Figure 2G). This finding ruled out numerical macrophage defects as the cause of macrophage death and showed that mTOR-deficient macrophages died because they were “intolerant” of mycobacterial infection.
To determine whether mTOR’s protective effect was macrophage-intrinsic, we compared mTOR mutant and WT macrophages in the same environment by creating WT-mTOR mutant parabionts with differentially labeled macrophages, red and yellow fluorescent in WT and mTOR mutants, respectively, and infecting both through their respective caudal veins (Figure 2H). By 4 dpi, mTOR mutant macrophages had been depleted by more than 90% on both WT and mTOR mutant sides of the parabionts, whereas WT macrophages persisted equally on both sides (Figure 2I). The depletion of mTOR mutant macrophages in these animals should not lead to Mm cording because the complement of WT macrophages should be able to engulf the infected mTOR mutant corpses and keep Mm intracellularly. By 4 dpi, as predicted, Mm was only found inside the WT macrophages (Figure 2J). In mTOR heterozygote-WT parabionts, mTOR heterozygote yellow fluorescent macrophages survived as well as WT red fluorescent macrophages, ruling out Tg(mpeg1:YFP) expression as an artifactual cause of macrophage depletion of mTOR mutant macrophages (Figures 2K and 2L). Thus, mTOR confers early cell-intrinsic protection against Mycobacterium-induced death.
Infected macrophage death in mTOR deficiency is associated with reduced mitochondrial membrane potential
Impairment in nutrient sensing pathways caused by mTOR-deficiency could sensitize cells to autophagic death or mitochondrial apoptosis (González et al., 2020; Green and Levine, 2014; Hosoi et al., 1999; Muthukkumar et al., 1995). To assess autophagic death, we created zebrafish deficient in the essential autophagy protein ATG12 (Bento et al., 2016). ATG12-deficient animals had defective autophagosome formation as evidenced by reduced LC3 aggregation (Figures S1A and S1B). However, ATG12 deficiency did not prevent death of mycobacterium-infected macrophages in rapamycin-treated animals (Figure S1C). To assess mitochondrial apoptosis, we used caspase-9 deficient zebrafish mutants (Galluzzi et al., 2016). Capase-9 mutants had the expected defect in developmental apoptosis as reflected by reduced dead cell debris in the brain at 3 days post-fertilization (dpf) (Figures S1D and S1E). However, rapamycin treatment induced death of their infected macrophages (Figure S1F). Thus, mTOR deficiency kills infected macrophages independent of inducing autophagy or mitochondrial apoptosis.
We ruled out two other modes of macrophage death commonly associated with mycobacterial infection—inflammasome-dependent, mediated through the adapter ASC, and type 1 interferon-dependent, mediated through the cytosolic DNA sensing adapter STING (Decout et al., 2021; Swanson et al., 2019). ASC or STING mutants had increased macrophage death when rendered mTOR-deficient (Figures S2G and S2H).
In contrast to mTOR deficiency, where macrophages died rapidly when bacterial burdens were still low, mycobacterium-induced macrophage death typically occurs with high intracellular bacterial burdens (Amaral et al., 2019; Beckwith et al., 2020; Clay et al., 2008; Lee et al., 2011), We had previously identified a case of macrophage death associated with low mycobacterial burdens, which was mediated through a pathway activated by dysregulated tumor necrosis factor (TNF) (Roca and Ramakrishnan, 2013; Roca et al., 2019). mTOR-deficient macrophage death did not involve this pathway; inhibition of essential components, the kinase RIP1 and the L-type calcium channels, failed to rescue death (Figures S1I–S1K). Moreover, mTOR-deficient infected macrophages produced less mitochondrial reactive oxygen species (mROS) than WT ones, in contrast to macrophage death in high TNF animals, which is initiated by excess mROS (Roca and Ramakrishnan, 2013; Roca et al., 2019; Figures 3A and 3B). mTOR-deficient macrophages had lower baseline mROS and a muted infection-induced increase, which only reached baseline WT levels (Figure 3B). mTOR regulates mitochondrial metabolism (Cunningham et al., 2007; Liu and Sabatini, 2020; Morita et al., 2013; Rambold and Pearce, 2018; Schieke et al., 2006); our findings suggested that mTOR-dependent increases in mitochondrial metabolism in response to mycobacterial infection constitute a protective metabolic adaptation that prevents pathogenic macrophage death.
To explore this further, we infected the THP-1 human macrophage cell line rendered mTOR-deficient by torin1 treatment. As in the zebrafish, mTOR deficiency increased macrophage death within 1-day post-infection, as indicated by staining with the cell membrane impermeant fixable viability dye eFluor 660 (Figures 3C and 3D). Moreover, tetramethylrhodamine ethyl ester (TMRE) staining showed that infection increased mitochondrial membrane potential in an mTOR-dependent manner (Murphy, 2009; Figures 3E and 3F). Consistent with defective mitochondrial metabolism, mTOR-deficient macrophages had slightly lower baseline ATP production, again with a muted infection-induced increase that only reached baseline WT levels (Figure 3G).
We found that infection increased mTORC1 signaling, as evidenced by increased phosphorylation of the ribosomal protein S6 (Battaglioni et al., 2022; Figures 3H–3K). Torin1-treated cells had a small increase in S6 phosphorylation, consistent with residual mTOR activity (Figures 3H and 3I). Notably, this increase only reached baseline WT levels, tracking with infection-induced increases in mitochondrial metabolism (mROS and TMRE) to baseline WT levels in mTOR-deficient conditions. Together, these findings suggest that baseline mTOR-facilitated mitochondrial metabolism is insufficient to protect macrophages from mycobacterium-induced death; adaptive infection-induced mTOR activity and corresponding increases in mitochondrial metabolism are required.
To determine whether death of infected mTOR-deficient macrophages was due to mitochondrial damage, we assessed cytochrome c release by flow cytometry (Lienard et al., 2020). More mTOR-deficient infected cells had released cytochrome c than uninfected cells, which had released hardly any (Figures 4A and 4B). To confirm that mitochondrial damage was the cause rather than the consequence of death, we checked whether mitochondrial depolarization preceded death. Macrophages infected with blue fluorescent Mm for 32 h were stained with TMRE, which is rapidly lost from the mitochondria upon loss of membrane potential, MitoTracker Deep Red (MTDR), a mitochondrial dye that is more resistant to changes in membrane potential, and Sytox Green, a cell membrane impermeant nucleic acid dye that labels dying cells. Widespread mitochondrial membrane depolarization (near total loss of TMRE) consistently preceded plasma membrane permeabilization and cell death (Sytox positivity) (Figures 4C and 4D; Video S3). MTDR staining outlasted TMRE staining while preceding Sytox positivity. Moreover, its loss was often incomplete at the time of Sytox positivity, consistent with some retention of mitochondrial architecture at the commencement of the death process. Thus, infection induces widespread mitochondrial damage in mTOR-deficient macrophages, causing cytochrome c release and death. Infection-induced increases in mTOR activity are adaptive, facilitating rapid increases in mitochondrial energy production, which appear to protect against this mycobacterium-mediated lethal mitochondrial damage.
mTOR deficiency sensitizes macrophages to mycobacterium-induced death by impairing glycolysis-dependent OXPHOS
Consistent with mTOR regulating a number of metabolic pathways that regulate mitochondrial metabolism, mTOR inhibition of THP-1 cells caused broad reductions in glycolysis, pentose phosphate pathways, and Krebs cycle metabolites (Düvel et al., 2010; Morita et al., 2013; Figure S3A). Correspondingly, glycolytic and respiratory capacity were reduced in mTOR-deficient cells with lower basal and ATP-coupled respiration and spare respiratory capacity (SRC) (Figures S3G–S3L). These deficits reflected compromised mitochondrial respiration and ATP production at baseline and a reduced ability to boost mitochondrial respiration in response to increased ATP demands. Moreover, mTOR deficiency blunted the small increase in mitochondrial metabolism that was apparent by 24 h post-infection (Figures S3H and S3I). At this early stage, however, infection did not alter glucose levels and glycolytic capacity, nor did it alter metabolite abundance in either WT or mTOR-deficient cells (Figures S3A–S3F and S3J–S3L). Consistent with mTOR deficiency impairing mitochondrial respiration by reducing glycolysis, selective inhibition of glycolysis with the glucose analog 2-deoxy-D-glucose (2DG) reduced Krebs cycle metabolites, mitochondrial respiration, and ATP production (Figures S3A, S3F, and S3M–S3O; Table S1).
Our findings were consistent with a model where mTOR-facilitated glycolytic fueling of the Krebs cycle drives the mitochondrial energy production required to protect infected macrophages from dying. If so, then inhibition of glycolysis should phenocopy mTOR deficiency, causing selective death of infected macrophages with impaired infection-induced increase in mitochondrial membrane potential. 2DG treatment induced both phenotypes in THP-1 cells, similar to torin1 treatment (Figures 5A and 5B). mTOR and glycolysis also had a cytoprotective effect in Mtb infection. To assess this, we used mc2 6206, the isogenic leucine and pantothenate auxotrophic mutant of the virulent H37Rv Mtb strain, a biosafety 2 level pathogen that elicits similar inflammatory responses and triggers diverse cell death programs (Beckwith et al., 2020; Mouton et al., 2019; Roca et al., 2019, 2022; Sampson et al., 2004, 2011). Mtb infection caused increased death of both mTOR-deficient and glycolysis-deficient THP-1 cells (Figure 5C). In the zebrafish, 2DG treatment depleted infected macrophages selectively and increased bacterial cording (Figures 5D–5G; Video S4). Thus, mTOR exerts its cytoprotective effect by supporting glycolysis both in Mm zebrafish infection and Mm- and Mtb-infected human macrophages.
Because glycolysis contributes to mitochondrial ATP production by supplying pyruvate to the Krebs cycle (Ryan and O'Neill, 2020), intercepting this step should also produce bacterial cording. Inhibition of the mitochondrial pyruvate carrier with UK5099 similarly increased bacterial cording (Halestrap, 1975; Figure 5H). mTOR-facilitated glycolysis also feeds the pentose phosphate pathway (Patra and Hay, 2014; Figure S2A). Zebrafish mutants deficient in glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway, did not have increased bacterial cording, ruling out the contribution of this pathway to mTOR-mediated resistance (Figures S3P and S3Q). Thus, mTOR deficiency sensitizes macrophages to Mm-induced mitochondrial damage and death by impairing glycolysis-dependent oxidative phosphorylation (OXPHOS) and thereby mitochondrial energy production. Consistent with this, genetic disruption of the electron transport chain complex 1 by targeting the assembly factor NDUFAF1 increased bacterial cording (Formosa et al., 2018; Figure 5I).
mTOR-dependent glycolysis and OXPHOS enable macrophages to resist mycobacterium ESAT-6-mediated death
The mTOR mutant had unmasked the potential of pathogenic mycobacteria to cause lethal mitochondrial damage in infected macrophages. We hypothesized that a specific mycobacterial determinant caused this damage. Our prime candidate was ESAT-6 secretion system 1 (ESX-1)because (1) it accelerates mycobacterium-induced macrophage death in WT (mTOR-sufficient) conditions, including in the zebrafish (Conrad et al., 2017; Davis and Ramakrishnan, 2009; Gröschel et al., 2016; Simeone et al., 2012, 2021; Volkman et al., 2004), and (2) it mediates mitochondrial damage in infected macrophages (Lienard et al., 2020; Wiens and Ernst, 2016). Whereas in WT macrophages, ESX-1-dependent death requires high intramacrophage bacterial burdens (Davis and Ramakrishnan, 2009; Volkman et al., 2004), we hypothesized that mTOR-deficiency sensitizes macrophages to ESX-1-mediated mitochondrial damage, causing death at low bacterial burdens. Consistent with our hypothesis, mTOR-deficient THP-1 macrophages infected with ESX-1-deficient Mm did not have increased cytochrome c release nor increased death (Figures 6A and 6B; Video S5). In mTOR-deficient zebrafish infected with ESX-1-deficient Mm, infected macrophages did not die (Figures 6C–6E; Video S6). ESX-1-deficient infection also did not cause macrophage death in animals deficient in glycolysis or OXPHOS (Figures 6F–6H). Thus, a mycobacterium-induced, mTOR-dependent increase in mitochondrial metabolism specifically counters ESX-1-dependent mitochondrial damage and cell death.
ESX-1-mediated damage of Mycobacterium-containing phagosomes is integral to its role in virulence (Lienard et al., 2020; Simeone et al., 2012, 2021). This process is facilitated by the mycobacterial cell surface lipid phthiocerol dimycoceroserate (PDIM); Mm mutants in the PDIM transporter MmpL7 are also impaired in phagosomal damage, as indicated by reduced galectin-8 (GAL8) recruitment (Augenstreich et al., 2017; Lerner et al., 2018; Osman et al., 2020; Quigley et al., 2017; Simeone et al., 2021; Cambier et al., 2014b; Figures S4A and S4B). To determine whether ESX-1-mediated phagosomal damage was integral to its mitotoxicity in mTOR-deficient macrophages, we tested the Mm mmpL7 mutant. mmpL7 mutant Mm infection did not kill mTOR-deficient macrophages, as evidenced by the lack of cording in the animals (Figure 6I). In contrast, Mm mutants in the virulence determinants Erp and MarP, which do not mediate phagosomal damage and promote intramacrophage growth through distinct mechanisms from ESX-1, did accelerate macrophage death in mTOR-deficient animals (Berthet et al., 1998; Cosma et al., 2006; Levitte et al., 2016; Vandal et al., 2008; Figures 6I, S4A, and S4B). Thus, ESX-1-dependent phagosomal permeabilization is a pre-requisite for its cytotoxicity to mTOR-deficient macrophages.
ESX-1’s membranolytic activity has been ascribed to its major secreted substrate, ESAT-6 (6 kDa early secretory antigenic target); however, pinning down its role versus those of other ESX-1 substrates has been complicated by their co-dependency for secretion, as deletion of ESAT-6 causes loss of other ESX-1 substrates (Bao et al., 2021; Champion et al., 2014; Fortune et al., 2005). Recent work has pinpointed a specific role for ESAT-6 in phagosomal damage and virulence by identifying point mutations in ESAT-6 that allow substantial levels of secretion of ESAT-6 and other ESX-1 substrates yet cause loss of phagosomal membrane damage and/or virulence (Brodin et al., 2005; Osman et al., 2022; Zhang et al., 2016). To test the specific role of ESAT-6-induced phagosomal damage in mediating cell death in mTOR deficiency, we used esxA (ESAT-6) mutant Mm expressing either of two such ESAT-6 C-terminal point mutations, M83I and M93T (Brodin et al., 2005; Osman et al., 2022). Mm-ESAT-6M83I and Mm-ESAT-6M93T infections did not kill macrophages in mTOR-deficient zebrafish (Figure 6J). Thus, ESAT-6 causes the phagosomal damage required for the cell death induced by mTOR deficiency.
mTOR enables infected macrophages to specifically resist ESAT-6-mediated mitochondrial damage
mTOR-deficiency might simply sensitize phagosomes to ESAT-6-mediated damage. However, mTOR-deficient and WT macrophages had similar ESAT-6-dependent increases in phagosomal damage, showing that this was not the case and instead suggesting that mTOR-deficient macrophages were sensitized to ESAT-6-mediated mitochondrial damage (Figure 7A, upper panels and 7B, black symbols).
ESAT-6 might mediate mitochondrial damage in mTOR-deficient macrophages indirectly or directly. In the indirect case, ESAT-6 would only be required to permeabilize phagosomes, enabling host lysosomal factors or other mycobacterial determinant(s) to access and damage mitochondria. In the direct case, ESAT-6 would also be required after the phagosome has been permeabilized. To distinguish between the two, we treated THP-1 cells with prazosin (PRZ), a drug that permeabilizes endo-lysosomal compartments in myeloid cells (Kozik et al., 2020). By 7 h of treatment, PRZ had caused extensive endo-lysosomal damage in uninfected control and mTOR-deficient macrophages (Figure S4C). In infected macrophages, PRZ caused similar increases in damaged WT and ESX-1-deficient mycobacterial phagosomes (Figures 7A and 7B). Moreover, the proportion of WT and ESX-1-mutant mycobacteria associated with damaged phagosomes was similar, showing that the PRZ-induced phagosomal permeabilization could equalize access of WT and ESX-1-deficient mycobacteria to the mitochondria (Figure 7C). Consistent with increasing bacterial exposure to mitochondria, PRZ increased cytochrome c release from WT-infected macrophages (Figure 7D). PRZ-treated ESX-1 mutant-infected macrophages had a much smaller increase in cytochrome c release and significantly lower than in untreated WT macrophages (Figure 7D). The small increase in cytochrome c release in ESX-1-mutant infection suggests that additional factors may also play a role, for instance, PDIM. To corroborate these conclusions in vivo, we assessed bacterial cording in zebrafish with and without PRZ treatment. As before, mTOR deficiency caused cording of WT but not ESX-1-deficient bacteria (Figure 7E). PRZ treatment of mTOR mutants increased ESX-1-mutant cording only slightly and significantly less than WT bacteria without PRZ (Figure 7E).
Next, we tested whether ESAT-6 was responsible for the mitochondrial damage by assessing bacterial cording of ESAT-6-mutant bacteria in zebrafish with and without PRZ treatment. As with ESX-1 mutant infections, PRZ treatment did not restore bacterial cording of ESAT-6 mutants (Figure 7F). These findings implicate ESAT-6 in mediating mitochondrial damage after first damaging the phagosome to enable access. ESAT-6 possesses both phagosomal and mitochondrial damaging activity and mTOR protects specifically against the latter. Our findings highlight the role of mTOR as a “counter-virulence” factor against ESAT-6 and indicate that even a small amount of ESAT-6 is sufficient to induce cytotoxicity in mTOR-deficient macrophages. mTOR-deficient macrophages tolerate infection with mycobacteria so long as they lack functional ESAT-6.
Discussion
Consistent with mTOR’s critical role in the development, homeostasis, and function of myeloid cells and T cells (Lachmandas et al., 2016; Powell et al., 2012; Sinclair et al., 2017; Weichhart et al., 2015), therapeutic mTOR blockade in organ transplantation and cancer has been associated with increased risk of infections, including TB (Fijałkowska-Morawska et al., 2011; Garcia and Wu, 2016; Jeon et al., 2017; Ruiz-Camps and Aguilar-Company, 2021; Tsai et al., 2007). This susceptibility has generally been ascribed to compromised adaptive immunity (Weichhart et al., 2015). We show here that mTOR deficiency results in profound, innate susceptibility to mycobacteria resulting from the rapid death of infected macrophages. This death results from catastrophic mitochondrial damage caused by mycobacterial ESAT-6. Thus, mTOR-facilitated mitochondrial metabolism represents a formidable armor against a potent mycobacterial mitotoxin. This study adds to the appreciation that while intracellular microbes can exploit host cell metabolism for growth and pathogenesis, the cells’ metabolic capabilities can also avert microbial attack (Pernas, 2021).
Our findings provide insight into the adaptive metabolic changes that occur upon mycobacterial infection. Stimulation of cultured macrophages with lipopolysaccharide (LPS), a major Gram-negative bacterial virulence determinant, induces a metabolic switch from mitochondrial OXPHOS to glycolysis under normoxic conditions (O'Neill and Pearce, 2016; Weichhart et al., 2015). This switch, which occurs through mTORC1 activation, enables macrophages to elaborate antimicrobial responses that depend on cataplerosis of Krebs cycle intermediates (O'Neill and Pearce, 2016). Whether Mtb infection induces this glycolytic switch is unclear; studies variably find that it boosts or represses glycolysis (Braverman et al., 2016; Cumming et al., 2018; Gleeson et al., 2016; Huang et al., 2018; Lachmandas et al., 2016; Olson et al., 2021; Shi et al., 2015). We find here that early in infection, Mm infection of cultured human macrophages induces OXPHOS without altering glycolysis. This is consistent with our findings in the zebrafish, where Mm- and Mtb-infected macrophages exhibit small increases in mitochondrial respiration early on (Roca et al., 2022). Although adaptive glycolytic shifts may occur later in infection, mTORC1’s role in early resistance to mycobacteria stems not from a glycolytic shift but from the boost in OXPHOS from its stimulation of glycolysis (Weichhart et al., 2015). This is demonstrated by our finding that directly inhibiting OXPHOS confers susceptibility.
How does ESAT-6 damage mitochondria? Mm and Mtb phagosomes frequently fuse to lysosomes, and contacts between lysosomes and mitochondria are proposed to facilitate metabolic exchanges between these organelles (Armstrong and Hart, 1971; Barker et al., 1997; Clemens and Horwitz, 1995; Harris et al., 2008; Levitte et al., 2016; Wong et al., 2018). The idea that mycobacterial phagolysosomes influence mitochondrial function is reinforced by the finding that mitochondria aggregate around these structures and undergo morphological changes (Jamwal et al., 2013; Mohareer et al., 2020). Given that direct contact is required for ESAT-6 permeabilization of host membranes (Conrad et al., 2017), ESAT-6 might specifically damage membranes of mitochondria that are in direct contact with permeabilized phagosomes. Indeed, ESX-1 is reported to cause some mitochondrial damage in mTOR-sufficient cells, as evidenced by reductions in mitochondrial mass, membrane potential loss, and release of cytochrome c and mitochondrial DNA (Chen et al., 2008; Fine-Coulson et al., 2015; Lienard et al., 2020; Pajuelo et al., 2018; Wiens and Ernst, 2016). The finding that in mTOR deficiency, infection with very few ESX-1/ESAT-6-expressing mycobacteria, likely confined to a single phagosome/phagolysosome, causes global loss of mitochondrial membrane potential suggests that there is rapid propagation of the initial localized damage. The lack of rapid repair or replacement of damaged mitochondria in the absence of mTOR-regulated biosynthetic processes may account for this (Cunningham et al., 2007; Liu and Sabatini, 2020; Morita et al., 2013; Morita et al., 2017; Rambold and Pearce, 2018; Schieke et al., 2006). Alternatively, reduced mitochondrial membrane potential has been shown to cause structural changes in the mitochondria—matrix condensation and unfolding of cristae—that facilitate cytochrome c release upon exposure to outer membrane disrupters like BAX family proteins (Gottlieb et al., 2003). Similar changes from mTOR deficiency could cause global mitochondrial catastrophe when subjected to ESAT-6’s mitotoxic effects. As in that report, we too find that disruption of respiration at complex I phenocopies the ESAT-6-mediated death produced by mTOR deficiency.
ESX-1 increases macrophage death, even in WT (mTOR competent) macrophages (Gröschel et al., 2016; Ramakrishnan, 2012; Augenstreich et al., 2017; Beckwith et al., 2020; Behar et al., 2010; Davis and Ramakrishnan, 2009; Srinivasan et al., 2014), with ESAT-6-mediated phagosomal damage being a pre-requisite step (Bao et al., 2021; Osman et al., 2022; Simeone et al., 2021; Srinivasan et al., 2014; Zhang et al., 2016). We show here that ESAT-6 induces phagosomal damage irrespective of whether the macrophage is mTOR-sufficient or -deficient. mTOR’s specific role is in resistance against ESAT-6-mediated catastrophic mitochondrial damage that rapidly kills the cell. We do not know whether ESAT-6 is sufficient for mitochondrial damage in mTOR deficiency. ESX-1 is responsible for plasma membrane damage in mTOR-sufficient cells and there, too, it is not clear exactly how damage is mediated—studies have variably implicated ESAT-6, other ESX-1 substrates, non-ESX-1 mycobacterial products, and excess lipoxins (Beckwith et al., 2020; Divangahi et al., 2009; Pagán and Ramakrishnan, 2018; Pajuelo et al., 2018). For the mitochondrial damage in mTOR deficiency, PDIM may facilitate ESAT-6’s role in addition to facilitating ESAT-6-mediated phagosomal damage.
TB is notorious for killing far more people over the millennia than any other infectious agent (Paulson, 2013). Yet, our recent epidemiological analyses show that most individuals clear Mtb infection through a combination of innate and adaptive immunity (Behr et al., 2018, 2019). Our work finds that tapping into mTOR-regulated homeostatic metabolic pathways constitutes a major host defense strategy. Curiously, these pathways protect against a specific mycobacterial virulence determinant, identifying mTOR as a counter-virulence factor against ESAT-6, where mTOR averts its catastrophic mitotoxicity to buy the host time to call in other “classical” immune defenses that can clear infection much of the time. In the minority of individuals, ESAT-6 and other mycobacterial virulence factors win out, allowing the evolutionary survival of the pathogen as well (Cambier et al., 2014a). Indeed, the modes of cell death that ESAT-6 produces in WT hosts through phagosomal or plasma membrane damage likely represent workarounds in mycobacterium’s pathogenic strategy (Beckwith et al., 2020; Chen et al., 2008; Divangahi et al., 2009; Pagán and Ramakrishnan, 2018; Pajuelo et al., 2018; Simeone et al., 2021; Zhang et al., 2021).
Therapies targeting mTOR are being explored for a number of conditions, including aging. Genetic and pharmacological mTOR inhibition can increase lifespan in yeast, worms, flies, and mice (Papadopoli et al., 2019; Saxton and Sabatini, 2017). Pilot studies of a short course of pharmacological mTOR inhibition in older human volunteers report increased responses to influenza vaccines (suggesting decreased immune senescence) and a reduction in self-reported viral respiratory infections (Mannick et al., 2014, 2018). Similarly, in lung TB patients receiving adjunctive mTOR inhibition therapy together with appropriate antimicrobial treatment had possible, transient improvement in lung function (Wallis et al., 2021). In a mouse model of severe TB, mTOR inhibition therapy induced host-beneficial or -detrimental effects depending on the treatment regimen; mTOR inhibition therapy reduced lung immunopathology in established infections when given in conjunction with an antimicrobial drug, but exacerbated lung damage and morbidity when administered alone in the early infection (Bhatt et al., 2021). Our finding that mTOR inhibitors dramatically increase susceptibility to pathogenic mycobacteria warrants caution in their use as anti-aging or immune boosting therapies in the many areas of the world with a high burden of TB.
Limitations of the study
How ESAT-6 causes the mitochondrial damage that ultimately triggers cell death in mTOR deficiency remains to be determined. ESAT-6 may directly permeabilize the outer membrane of mitochondria in close proximity to permeabilized phagosomes or induce mitochondrial damage by cooperating with host or mycobacterial molecules with intrinsic mitotoxic activity. Furthermore, how reductions in mitochondrial membrane potential specifically increase sensitivity to ESAT-6-mediated mitotoxicity remains unclear. Identifying the molecular players in the cell death cascade and the alterations in mitochondrial structure and function in mTOR deficiency, and specifically in response to ESAT-6-mediated damage, should help to clarify these processes.
STAR★Methods
Key resources table
REAGENT or RESOURCE | SOURCE | IDENTIFIER |
---|---|---|
Antibodies | ||
AlexaFluor 488 anti-cytochrome c (clone 6H2.B4) | BioLegend | Cat# 612308; RRID:AB_2565240 |
Phospho-S6 Ribosomal Protein (S235/S236) XP rabbit (clone D57.2.2E) (Alexa Fluor 647 Conjugate) | Cell Signaling Technology | Cat# 4851; RRID:AB_10695457 |
S6 Ribosomal Protein (clone 54D2) Mouse mAb (Alexa Fluor 647 Conjugate) | Cell Signaling Technology | Cat# 5548; RRID:AB_10707322 |
Goat IgG anti-human Galectin-8 | R&D Systems | Cat# AF1305; RRID:AB_2137229 |
Donkey anti-goat IgG (H+L), Alexa Fluor 488 | Thermo Fisher Scientific | Cat# A-11055; RRID:AB_2534102 |
Optical-bottom tissue culture plates | ||
96-well (half area) black plate with transparent bottom | Greiner Bio-One | Cat# 675090 |
VisiPlate 24-well black plate with clear bottom | Perkin Elmer | Cat# 1450–606 |
6-well No. 1.5 coverslip, 20 mm glass diameter, uncoated plate | MatTek | Cat# P06G-1.5-20-F |
24-well No. 1.5 coverslip, 13 mm glass diameter, uncoated plate | MatTek | Cat# P24G-1.5-13-F |
Bacterial and virus strains | ||
M. marinum M strain transformed with pmsp12::BFP2 | Takaki et al., 2013 | Derivative of ATCC # BAA-535 |
M. marinum M strain transformed with pmsp12::mWasabi | Takaki et al., 2013 | Derivative of ATCC # BAA-535 |
M. marinum M strain transformed with pmsp12::tdTomato | Takaki et al., 2013 | Derivative of ATCC # BAA-535 |
M. marinum M strain transformed with pmsp12::tdKatushka2 | Takaki et al., 2013 | Derivative of ATCC # BAA-535 |
ΔESX1 M. marinum M strain transformed with pmsp12::tdTomato | Pagán et al., 2015 | Derivative of ATCC # BAA-535 |
ΔmmpL7 M.marinum M strain transformed with pmsp12::tdTomato | Cambier et al., 2014b | Derivative of ATCC # BAA-535 |
Δerp M. marinum M strain transformed with pmsp12::tdTomato | Takaki et al., 2013 | Derivative of ATCC # BAA-535 |
marP::Tn M. marinum M strain transformed with pmsp12::tdTomato | Levitte et al., 2016 | Derivative of ATCC # BAA-535 |
ΔesxA M. marinum M strain transformed with pmsp12::tdTomato | Osman et al., 2022 | Derivative of ATCC # BAA-535 |
ΔesxA M. marinum M strain transformed with ::esxAWT | Osman et al., 2022 | Derivative of ATCC # BAA-535 |
ΔesxA M. marinum M strain transformed with ::esxAM83I | Osman et al., 2022 | Derivative of ATCC # BAA-535 |
ΔesxA M. marinum M strain transformed with ::esxAM93T | Osman et al., 2022 | Derivative of ATCC # BAA-535 |
M. tuberculosis ΔleuDΔpanCD mc2 6206 transformed with pmsp12::tdTomato | Roca et al., 2019 | N/A |
Chemicals, peptides, and recombinant proteins | ||
BD Difco Middlebrook 7H9 broth (dehydrated) | Fisher Scientific | Cat# DF0713-17-9 |
Middlebrook 7H10 agar base | Sigma-Aldrich | Cat# M0303 |
L-leucine | Sigma-Aldrich | Cat# L8000; CAS: 61-90-5 |
Calcium pantothenate | Sigma-Aldrich | Cat# C8731; CAS: 137-08-6 |
Remel OADC Enrichment | Fisher Scientific | Cat# 11903262 |
RPMI 1640 medium | Sigma-Aldrich | Cat# R7509 |
Gibco Phenol-free RPMI | Thermo-Fisher | Cat# 11835030 |
XF DMEM, pH 7.4 | Agilent | Cat# 103575-100 |
Instant Ocean Salt | ZM Systems | N/A |
PTU (1-phenyl-2-thiourea) | Sigma-Aldrich | Cat# P7629; CAS: 103-85-5 |
Tango Buffer (10x) | Thermo Fisher | Cat# BY5 |
Phenol Red Sodium Salt | Sigma-Aldrich | Cat# P5530; CAS: 34487-61-1 |
Pronase | Sigma-Aldrich | Cat# P5147; CAS:9036-06-0 |
Tricaine (ethyl 3-amonobenzoate, methanesulfonic acid salt) | Fisher Scientific | Cat# 10743661; CAS: 886-86-2 |
TopVision Low Melt Agarose | Thermo Fisher | Cat# R0801 |
Rapamycin | Sigma-Aldrich | Cat# R0395; CAS: 53123-88-9 |
Torin1 | Cambridge Bioscience | Cat# CAY10997; CAS: 1222998-36-8 |
Nifedipine | Cambridge Bioscience | Cat# N3228; CAS: 21829-25-4 |
Diltiazem HCl | Cambridge Bioscience | Cat# D3447; CAS: 33286-22-5 |
2DG (2-deoxy-D-glucose) | Sigma-Aldrich | Cat# D8375; CAS: 154-17-6 |
UK5099 | Cambridge Bioscience | Cat# B1952; CAS: 56396-35-1 |
Digitonin | Acros | Cat# 407565000 CAS: 11024-24-1 |
Prazosin HCl | Sigma-Aldrich | Cat#: P7791; CAS: 19237-84-4 |
PMA (Phorbol 12-myristate 13-acetate) | Sigma-Aldrich | Cat#: P1585; CAS: 16561-29-8 |
Accutase | Sigma-Aldrich | Cat#: A6964 |
Paraformaldehyde, 16% w/v | Alfa Aesar | Cat# 11490570 |
Acridine Orange (2% solution in H20) | Sigma-Aldrich | Cat# A9231; CAS: 65-61-2 |
MitoTracker Red CM-H2Xros | Thermo Fisher | Cat# M7513 |
eBioscience Fixable Viability Dye eFluor 660 | Thermo Fisher | Cat# 65-0864-14 |
Tetramethylrhodamine, ethyl ester | Abcam | Cat# ab113852 |
SYTOX Green Nucleic Acid Stain | Thermo Fisher | Cat# S7020 |
AMPure XP beads for PCR Purification | Beckman Coulter | Cat# A63881 |
Precision Melt Supermix | BioRad | Cat# 172-5112 |
KASP V4.0 2X Master Mix | LGC Biosearch | Cat# KBS-1016-002 |
Mammalian Cell Lysis Buffer 5x | Abcam | Cat# ab179835 |
Alt-R Sp Cas9 Nuclease V3 | IDT | 1081058 |
Critical commercial assays | ||
Gibson Assembly Cloning Kit | New England BioLabs | Cat# E5510S |
mMessage mMachine T7 Transcription Kit | Thermo Fisher | Cat# AM1344 |
Seahorse XFp Glycolytic Rate Assay Kit | Agilent | Cat# 103346-100 |
Seahorse XFp Mito Stress Test Kit | Agilent | Cat#103015-100 |
ATP Assay Kit (Colorimetric/Fluorometric) | Abcam | Cat# ab83355 |
Glucose-6-Phosphate Dehydrogenase Activity Assay Kit (Fluorometric) | Abcam | Cat# ab176722 |
Experimental models: Cell lines | ||
THP-1 | ATCC | Cat# TIB-202, RRID:CVCL_0006 |
Experimental models: Organisms/strains | ||
Zebrafish (Danio rerio): wild type AB strain | University of Cambridge | ZDB-GENO-960809-7 |
Zebrafish: TL strain | University of Cambridge | ZDB-GENO-990623-2 |
Zebrafish: WIK strain | University of Washington | ZDB-GENO-010531-2 |
Zebrafish: Tg(mpeg1:YFP)w200 | Roca and Ramakrishnan, 2013 | ZDB-ALT-130130-3 |
Zebrafish: Tg(mpeg1:Brainbow)w201 | Pagán et al., 2015 | ZDB-ALT-150512-3 |
Zebrafish: Tg(mfap4:tdTomato-CAAX)xt6 | Walton et al., 2015 | ZDB-ALT-160122-3 |
Zebrafish: Tg(ubib:secA5-YFP)cu34 | This work | N/A |
Zebrafish: Tg(CMV:EGFP-map1lc3b)zf155 | He et al., 2009 | ZDB-ALT-091029-2 |
Zebrafish: Tg(lysC:EGFP)nz117 | Hall et al., 2007 | ZDB-ALT-071109-2 |
Zebrafish: Tg(cd41:GFP) | Lin et al., 2005 | N/A |
Zebrafish: pycardw216 | Matty et al., 2019 | ZDB-ALT-191009-1 |
Zebrafish: mtorfh178 | This work | N/A |
Zebrafish: mtorsa16755 | Wellcome Trust Sanger Institute | ZDB-ALT-131217-12934 |
Zebrafish: rptorsa11537 | Wellcome Trust Sanger Institute | ZDB-ALT-130530-177 |
Zebrafish: rictorasa15967 | Wellcome Trust Sanger Institute | ZDB-ALT-130411-4494 |
Zebrafish: rictorbsa18403 | Wellcome Trust Sanger Institute | ZDB-ALT-131217-14421 |
Zebrafish: atg12sa42684 | Wellcome Trust Sanger Institute | ZDB-ALT-160601-8392 |
Zebrafish: casp9sa11164 | Wellcome Trust Sanger Institute | ZDB-ALT-130411-1023 |
Zebrafish: sting1sa35634 | Wellcome Trust Sanger Institute | ZDB-ALT-160601-4021 |
Zebrafish: g6pdsa24272 | Wellcome Trust Sanger Institute | ZDB-ALT-161003-11894 |
Oligonucleotides | ||
mtorfh178 forward primer for genotyping by HRMA 5’-TCACAGTATCAGATCTTCATTCCTATGGT-3’ |
This paper | N/A |
mtorfh178 reverse primer for genotyping by HRMA 5’-ACATCATAGCGCTGGTGATTGAT-3’ |
This work | N/A |
mtorsa16755 forward primer for genotyping by HRMA 5’-TGACTACAGCACCAGCGAGA-3’ |
This work | N/A |
mtorsa16755 reverse primer for genotyping by HRMA 5’-ATGGTGTGGTGATTGGACAG-3’ |
This work | N/A |
Alt-R crRNA Dr.Cas9.NDUFAF1.1.AA 5’-TGGAACAGACCCGTGTCGTG-3’ |
IDT | N/A |
Alt-R crRNA Dr.Cas9.NDUFAF1.1.AB 5’-TATCGAGTCTCTCCATCACG-3’ |
IDT | N/A |
Alt-R crRNA Dr.Cas9.NDUFAF1.1.AC 5’-GGTCCCATACAGCAAACACG-3’ |
IDT | N/A |
Alt-R crRNA Dr.Cas9.NDUFAF1.1.AD 5’-CGTGTGTCTGGAGGCTGACC-3’ |
IDT | N/A |
Alt-R CRISPR-Cas9 tracrRNA | IDT | 1073191 |
Forward primer for genotyping ndufaf1 AA mutagenesis by HRMA 5’-AGAGCACATGCTGGAACAGA-3’ |
This work | N/A |
Reverse primer for genotyping ndufaf1 AA mutagenesis by HRMA 5’-TGTTTTTGCCCAGACTGACA-3’ |
This work | N/A |
Forward primer for genotyping ndufaf1 AB, AC mutagenesis by HRMA 5’-CGCAGTGTGGCTTATGTCAG-3’ |
This work | N/A |
Reverse primer for genotyping ndufaf1 AB, AC mutagenesis by HRMA 5’-TTGGAGCGCATAGAGCAGTA-3’ |
This work | N/A |
Forward primer for genotyping ndufaf1 AD mutagenesis by HRMA 5’-AGGAGCAAGTTTGAGCGAGA-3’ |
This work | N/A |
Reverse primer for genotyping ndufaf1 AD mutagenesis by HRMA 5’-AAGCCAAAGTGCTTCCTGAC-3’ |
This work | N/A |
pDestTol2pA2_ubi:EGFP forward primer for vector fragment amplification for Gibson Assembly 5’-GGCGGTGGAAGATCTGGG-3’ |
This work | N/A |
pDestTol2pA2_ubi:EGFP reverse primer for vector fragment amplification for Gibson Assembly 5’-GGTCCAGCCTGCTTTTTTG-3’ |
This work | N/A |
secA5-YFP forward primer for insert fragment amplification for Gibson Assembly 5’-aaagcaggctggaccATGCATAAGGTTTTGCTG-3’ |
This work | N/A |
secA5-YFP reverse primer for insert fragment amplification for Gibson Assembly 5’-agatcttccaccgccGATGAATTAATTCGAGCTCC-3’ |
This work | N/A |
ubb:secA5 joint sequence forward primer to validate assembled product 5’-TCGTTTAACATGGGAGAAGTGC-3’ |
This work | N/A |
ubb:secA5 joint sequence reverse primer to validate assembled product 5’-AGCCTTTCATAGCCTTCCGA-3’ |
This work | N/A |
YFP-SV40pA joint sequence forward primer to validate assembled product 5’-CTGTACAAGTAAAGCGGCCG-3’ |
This work | N/A |
YFP-SV40pA joint sequence reverse primer to validate assembled product 5’-GTAAAACGACGGCCAGTGAA-3’ |
This work | N/A |
Recombinant DNA | ||
T7-TPase | Khattak et al., 2014 | RRID:Addgene_51818 |
pDestTol2pA2_ubi:EGFP | Mosimann et al., 2011 | RRID:Addgene_27323 |
pBH-UAS-secA5-YFP | van Ham et al., 2010 | RRID:Addgene_32359 |
pTol2-ubb:secA5-YFP | This work | N/A |
Software and algorithms | ||
NIS Elements (5.21) | Nikon | N/A |
IMARIS (8.2) and IMARIS for Cell Biologists (9.1) | Bitplane | N/A |
FlowJo 10 | TreeStar | N/A |
Prism (versions 7 and 9) | GraphPad | N/A |
ImageJ | https://imagej.nih.gov/ij/ | N/A |
Fluorescent Pixel Count Macro (Image J) | Takaki et al., 2013 | N/A |
AssayR | Wills et al., 2017 | N/A |
MetaboAnalyst 5.0 | Pang et al., 2021 | N/A |
Photoshop CS6 | Adobe | N/A |
Illustrator CS6 | Adobe | N/A |
Resource availability
Lead contact
Additional information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lalita Ramakrishnan (lalitar@mrc-lmb.cam.ac.uk).
Materials availability
Plasmids and zebrafish lines generated in this study are available from the lead contact.
Data and code availability
-
•
Microscopy and flow cytometry data reported in this paper will be shared by the lead contact upon request. The unprocessed metabolomics data generated in this study are available from the lead contact.
-
•
This paper does not report original code.
-
•
Any additional information needed to reanalyze the data reported in this paper is available from the lead contact upon request.
Experimental model and subject details
Ethics statement
Zebrafish husbandry and experiments were carried out in compliance with guidelines from the UK Home Office and the US Public Health Service Policy on Human Care and Use of Laboratory Larvae using protocols approved by the Animal Welfare and Ethical Review Body of the University of Cambridge and the Institutional Animal Care and Use Committee of the University of Washington, respectively.
Zebrafish husbandry and infections
Zebrafish embryos and larvae (of undetermined sex due to their early stages of development) of the wild-type AB strain (Zebrafish International Resource Center, ZIRC), TL strain (ZIRC), or of mixed AB/TL backgrounds were used in experiments. The Tg(mpeg1:YFP)w200, Tg(mpeg1:Brainbow)w201 (described as mpeg1:tdTomato), Tg(mfap4:tdTomato-CAAX)xt6, Tg(CMV:EGFP-map1lc3b)zf155, Tg(lysC:EGFP)nz117 , Tg(cd41:GFP), and Tg(ubb:secA5-YFP)cu34 (this work) fluorescent reporter lines were maintained in the AB strain (Hall et al., 2007; He et al., 2009; Lin et al., 2005; Pagán et al., 2015; Roca and Ramakrishnan, 2013; Walton et al., 2015). The pycardw216 mutant line (Matty et al., 2019) and mtorfh178 mutant line (this work) were generated and maintained in the AB strain. The mtorsa16755, rptorsa11537, rictorasa15967, rictorbsa18403, atg12sa42684, casp9sa11164, sting1sa35634, and g6pdsa24272 mutant lines (Wellcome Trust Sanger Institute) (Kettleborough et al., 2013) were generated in the TL strain and maintained in either the TL strain (rictorasa15967, rictorbsa18403, and g6pdsa24272) or mixed AB/TL backgrounds (mtorsa16755, rptorsa11537, and atg12sa42684, casp9sa11164, and sting1sa35634). Zebrafish of the WIK strain (ZIRC) were used to map mtorfh178. Zebrafish were maintained in buffered reverse osmotic water systems under a 14-hr light/10-hr dark cycle. Zebrafish larvae were fed paramecia twice daily, while juvenile and adult zebrafish were fed at least twice a day with dry food and brine shrimp. Zebrafish embryos were collected and cultured in reverse osmosis water containing 0.18g/L Instant Ocean Salt supplemented with 0.25μg/mL methylene blue at 28.5°C. On 1 dpf, embryos to be used in experiments were transferred to 0.5x E2 medium (7.5mM NaCl, 0.25mM KCl, 0.5mM MgSO4, 0.075mM KH2PO4, 0.025mM Na2HPO4, 0.5mM CaCl2, and 0.35mM NaHCO3) supplemented with 0.003% PTU (1-phenyl-2-thiourea, Sigma) to inhibit melanin synthesis.
For infections, 2 dpf larvae of undetermined sex (due to early developmental stage) were dechorionated manually or with ≤0.5mg/mL pronase (Sigma-Aldrich) and then anesthetized with fish water containing 0.025% tricaine (Sigma). Larvae were injected via the caudal vein or the hindbrain ventricle using single-cell suspensions of Mm of known titer to deliver ∼100 - 250 bacteria per 3 – 5 nL injection as previously described (Takaki et al., 2013). Phenol red sodium salt (≤ 1% w/v diluted in PBS, Sigma-Aldrich) was used as an injection tracer. Inoculums were confirmed by injecting onto Middlebrook 7H10 agar plates (supplemented with oleic acid, albumin, dextrose, and Tween-80 plus hygromycin B or kanamycin, as appropriate. For experiments with mutant lines, wild-type and heterozygous siblings were used as comparators, animals were genotyped after data acquisition. In experiments involving drug treatments, infected animals were randomly assigned to treatment groups. Unless indicated, treatments were initiated immediately after infection via soaking, and drug exposure was maintained until the experimental endpoint. UK5099 (Cambridge Bioscience) was changed daily.
THP-1 macrophage culture and infections
Monocytic human THP-1 cells (ATCC) were grown at 37°C, 5% CO2 in RPMI medium (Sigma-Aldrich) supplemented with 10% FBS (Gibco), L-glutamine (Gibco), Penicillin, and Streptomycin (complete RPMI). To differentiate THP-1 cells into macrophages, cells were seeded at 5 x 105 cells/mL in flat-bottomed tissue culture plates (2.5 x 105 cells/well of 24-well plate) and stimulated with 100nM PMA Phorbol 12-myristate 13-acetate (Sigma-Aldrich) for two days. The resulting adherent cells were then washed with complete RPMI and rested for two days prior to infection. For microscopy experiments, cells were plated on optical bottom plates (Perkin Elmer or MatTek). Cells were pre-incubated overnight with pharmacological compounds or matching concentrations of vehicle (≤0.5% DMSO). On the infection day, cells were washed with antibiotic-free complete RPMI and infected with single-cell suspensions of Mm or Mtb for five hours in a 33°C, 5% CO2 incubator (for Mm) and 37°C, 5% CO2 incubator (for Mtb). After infection, cells were washed with antibiotic-free complete RPMI supplemented with the corresponding pharmacological compounds and returned to the appropriate incubators. For experiments with the leucine and pantothenate double auxotroph ΔleuDΔpanCD Mtb, complete RMPI was also supplemented with 0.05 mg/mL L-leucine and 0.024 mg/mL calcium pantothenate (Sigma-Aldrich). Multiplicity of infection was determined by calculating the number of mycobacterial colony forming units (CFU) per cells plated in each well.
Method details
Bacterial strains
M. marinum M strain (ATCC #BAA-535) and its mutant derivatives ΔESX-1, ΔmmpL7, Δerp, marP::tn, and ΔesxA expressing BFP2, mWasabi, tdTomato, or tdKatushka2 under the control of the msp12 promoter (Cambier et al., 2014b; Cosma et al., 2006; Levitte et al., 2016; Osman et al., 2022; Takaki et al., 2013) were grown at 33°C under hygromycin B (Cambridge Bioscience) or kanamycin (Sigma-Aldrich) selection in Middlebrook 7H9 medium (BD Difco) supplemented with oleic acid, albumin, dextrose, and Tween-80 (Sigma-Aldrich) (Takaki et al., 2013). M. tuberculosis ΔleuDΔpanCD mc2 6206 expressing msp12:tdTomato was grown at 37°C under hygromycin B and kanamycin selection in Middlebrook 7H9 medium supplemented with oleic acid, albumin, dextrose, Tween-80, catalase, and 0.05 mg/mL L-leucine and 0.024 mg/mL calcium pantothenate (Sigma-Aldrich) (Roca et al., 2019; Sampson et al., 2011).
Zebrafish genotyping
DNA from adult fin clips or whole larvae was extracted using the HotSHOT method (Truett et al., 2000). Animals were genotyped by High Resolution Melt Analysis (HRMA) of PCR products (Garritano et al., 2009) or by Kompetitive Allele-Specific PCR (KASP) assay (LGC Biosearch) (He et al., 2014) in a CFX Connect thermocycler (BioRad). DNA from 2DG-treated animals was purified with AMPure XP beads (Beckman Coulter) according to the manufacturer’s instructions prior to PCR.
Mapping of mtorfh178
Zebrafish carrying the fh178 allele were outcrossed to the WIK strain for mapping as previously described (Tobin et al., 2010). fh178 was mapped to chromosome 8 initially between the markers z7370 and z14670. Further mapping defined a critical two-gene interval that included mtor and qars1 to the right of a single nucleotide polymorphism in the 3’ end of angptl7 (1 recombination in 302 meioses) and to the left of a polymorphism in intron 2 of ogg1 (2 recombinations in 300 meioses). Sequencing of cDNAs isolated from mutants and wild-type animals in the critical region identified a stop codon in exon 24 of mtor in the mutant but not wild-type animals. This mutation segregated absolutely with the fh178 mutants (no recombinants).
Creation of Tg(ubb:secA5-YFP)cu34
The Tol2 ubb:secA5-YFP plasmid was assembled from PCR-amplified fragments of pDestTol2pA2_ubi:EGFP (RRID: Addgene 27323) (Mosimann et al., 2011) and pBH-UAS-secA5-YFP (RRID: Addgene 32359) (van Ham et al., 2010) the Gibson Cloning kit (New England Biolabs). Correct plasmid assembly was confirmed by diagnostic PCR of joined segments and by Sanger sequencing. Tol2 transposase (RRID: Addgene 51818) (Khattak et al., 2014) was in vitro transcribed with the T7 mMessage/mMachine kit (Thermo Fisher) according to the manufacturer’s instructions. Tol2 ubb:secA5-YFP plasmid and transposase mRNA were co-injected into one-cell embryos of the wild-type AB strain as previously described (Suster et al., 2011). G0 larvae expressing the transgene were identified by fluorescence microscopy and raised to adulthood. Potential founders were identified through pairwise crosses of G0 adults and non-transgenic AB fish. A single F1 transgenic animal was used to establish the line.
CRISPR-Cas9 mutagenesis
The mutagenesis procedure was adapted from published methods (Burger et al., 2016; Wu et al., 2018). Guide RNAs (60 μM) were generated by complexing equimolar amounts of Alt-R tracrRNA and individual ndufaf1-specific Alt-R crRNAs (Dr.Cas9.NDUFAF1.1.AA, AB, AC, and AD; IDT) in nuclease-free Duplex Buffer (IDT) at 95°C for 5 minutes. Aliquots of complexed RNA were stored at -20°C. To produce ribonucleoprotein complexes (RNPs) (10 μM), guide RNA pools were combined with Alt-R Sp Cas9 Nuclease V3 (IDT) at an equimolar ratio of total RNA to Cas9 in working buffer (20 mM HEPES, 150 mM KCl, pH 7.5) and incubated at 37°C for 10 minutes. Wild-type zebrafish of the AB strain were injected at the 1-cell stage with ∼2 nL of RNP to create G0 crispants or ∼2nl of working buffer to produce unmutagenized experimental control animals. Mutagenesis was assessed in individual animals by HRMA of PCR amplicon spanning each of the CRISPR targets.
Parabiosis
Parabiosis of zebrafish embryos was performed as previously described (Demy et al., 2013). Briefly, blastulae derived from synchronized mtorfh178/+; Tg(mpeg1:YFP)w200 and Tg(mpeg1:tdTomato) incrosses were manually dechorionated, paired, scratched with an aluminum silicate microinjection needle, and allowed to fuse in high-calcium Ringer’s solution (116 mM NaCl, 2.9 mM KCl, 10 mM CaCl2, 5 mM HEPES, pH 7.2) supplemented with 50 U/mL penicillin and 50 U/mL streptomycin. Only parabiotic pairs fused at the head, devoid of gross morphological abnormalities, and sharing blood circulation were used in experiments. On 2 dpf, each parabiotic animal was infected via the caudal vein to ensure similar distribution of mycobacteria between the pair’s caudal hematopoietic tissues. The bodies of each parabiotic pair were micro-dissected and individually genotyped after completion of the experiment.
Microscopy and image analyses
Widefield fluorescence microscopy was performed as previously described (Takaki et al., 2013). Bacterial burdens were determined with a Nikon Eclipse Ti-E inverted microscope using a 4x objective and running a fluorescent pixel counts macro in ImageJ (National Institutes of Health) (Takaki et al., 2013). Macrophages were counted manually with a Nikon Eclipse E600 upright microscope using a 20x objective. For serial imaging of individual zebrafish, larvae were housed individually in 96-well plates under standard husbandry conditions.
Laser scanning confocal microscopy was performed as described (Pagán et al., 2015). Larvae were anesthetized in PTU-supplemented 0.5x E2 medium containing 0.025% tricaine and embedded in 2% low melt agarose (TopVision) on optical-bottom plates (MatTek). Imaging was performed with a Nikon A1R confocal microscope using 20x or 40x objectives and the galvano or resonant scanners. 0.9 - 2 μm optical sections were combined to generate 15 - 60 μm z stacks. For time-lapse microscopy of zebrafish larvae, imaging was done at 27°C using a microscope incubator (Okolab), using acquisition intervals of 2 - 5 minutes for 6 hours. For serial imaging of individual zebrafish, larvae were removed from the agarose using jeweler’s forceps and housed individually under standard husbandry conditions. For time-lapse microscopy of Mm-infected THP-1 cells, samples were imaged at 33°C, 5% CO2 in antibiotic-free, phenol-free complete RPMI containing 50 nM SYTOX Green nucleic acid stain (Invitrogen) for 4 hours.
The acquired images were processed using the denoising feature in the Elements software (Nikon). The surface rendering feature of Imaris (Bitplane) was used to quantify intramacrophage bacterial burdens and mROS levels; the number of acridine orange foci in the midbrain and LC3 puncta in neuromasts, clusters of mechanosensory hair cells of the lateral line in fish; phospho-S6 and total S6 MFIs, and the frequencies of galectin-8-associated Mm per imaging field (Thomas et al., 2015). The numbers of dying macrophages and macrophages with galectin-8-decorated Mm foci were counted manually.
Acridine orange staining
Zebrafish larvae were transferred to 1.5 mL microcentrifuge tubes and stained with 1 mL of 2.4μg/mL acridine orange in 0.5x E2 medium with PTU for 30 minutes with rotation and protected from light (Roca et al., 2019). Stained larvae were then rinsed in 0.5x E2 medium with PTU and imaged by confocal microscopy.
Mitochondrial vital dye staining
Zebrafish larvae were injected with ∼1 nL of 10 mM MitoTracker Red CMXH2-Xros via the caudal vein immediately prior to imaging by confocal microscopy (Roca and Ramakrishnan, 2013).
THP-1 macrophages were incubated with 40nM MitoTracker Deep Red (Thermo Fisher) and/or 100 nM tetramethylrhodamine, ethyl ester (TMRE) (Abcam) for 20 minutes in a 37°C, 5% CO2 incubator according to the manufacturers’ instructions. For flow cytometric analysis of TMRE, cells were then washed with complete RPMI media, stained with FVD eF660, and run without chemical fixation.
Immunostaining
The staining procedure was performed as previously described (Osman et al., 2020). THP-1 cells were fixed in PFA solution (4% w/v paraformaldehyde in PBS) at room temperature (RT) for at least 30 minutes. Cells were then washed twice with PBS and incubated in permeabilization/block (PB) solution (0.1% Triton-X 100, 1% bovine serum albumin in PBS) for 30 minutes at RT, and subsequently stained with Alexa Fluor 647-conjugated rabbit anti-phospho-S6S235/S236 or total S6 (Cell Signaling Technology) or goat anti-human galectin-8 antibody (R&D Systems) diluted in PB solution overnight at 4°C. The following day, cells stained with the galectin-8 antibody were washed three times with PBS and stained with Alexa Fluor 488-conjugated donkey anti-goat IgG (Thermo Fisher) in PB solution for one hour at RT. Cells were then washed three times with PBS and maintained in PBS for imaging by confocal microscopy. In some experiments, cells nuclei were stained with Hoechst 33342 (10μg/mL) for 20 minutes at RT prior to imaging.
Flow cytometry
THP-1 macrophages were stained with eBioscience Fixable Viability Dye (FVD) eFluor 660 (Thermo Fisher), detached with Accutase (Sigma-Aldrich), and transferred to polystyrene FACS tubes (Sarstedt). Single-cell suspensions were washed with MACS buffer (0.5% bovine serum albumin, 2mM EDTA in PBS, ph7.2) at 290 x g for 5 minutes at 4°C, and in most cases, fixed in 4% PFA solution overnight at 4°C. The following day, samples were washed with and resuspended in MACS buffer. Data were acquired in LSRII or Fortessa flow cytometers (BD Biosciences) and analyzed in FlowJo 10 (TreeStar), gating on single-cell events.
Cytochrome c release assay
The cytochrome c release assay was adapted from Lienard et al. (2020). 7 hours after infection with tdTomato-expressing Mm, cells were stained with eBioscience Fixable Viability Dye (FVD) eFluor 660 (Thermo Fisher), detached with Accutase (Sigma-Aldrich), transferred to polystyrene FACS tubes (Sarstedt), and washed first with ice-cold MACS buffer (0.5% bovine serum albumin, 2mM EDTA in PBS, ph7.2) and then ice-cold PBS by centrifugation at 290 x g for 5 minutes at 4°C. Cells were incubated in ice-cold permeabilization buffer (50 μg/mL digitonin, 100 mM KCl) for 5 minutes and immediately fixed in 4% PFA solution to stop the permeabilization reaction. Cells were then centrifuged as above and fixed overnight in 4% PFA solution at 4°C. Samples were subsequently permeabilized with eBioscience Permeabilization Buffer (Thermo Fisher) and stained with AlexaFluor 488 anti-cytochrome c antibody (BioLegend) for 2 hours at room temperature. Samples were analyzed by flow cytometry by gating on the viable, infected (FVD eFluor 660- tdTomato+) single-cell events.
ATP quantification
ATP levels were quantified by fluorimetry in a CLARIOStar Plus (BMG Labtech) microplate reader using the ATP Assay Kit (Abcam) according to the manufacturer’s instructions. 106 THP-1 macrophages were analyzed per replicate.
Measurement of G6PD activity
Individual 5 dpf larvae from an g6pdsa24272/+ incross were lysed using Mammalian Cell Lysis Buffer (Abcam). A small amount of each lysate was used to genotype the larvae. G6PD activity in individual larvae was determined by fluorimetry in a CLARIOStar Plus (BMG Labtech) microplate reader using the G6PD Activity Assay Kit (Abcam) according to the manufacturer’s instructions.
Metabolic analyses
For metabolite quantification, THP-1 cells (2 x 106 cells/sample, four replicates/condition) were washed in ice-cold PBS, and metabolites were extracted with 150 μL extraction buffer (50:30:20, methanol:acetonitrile:water) cooled on dry ice for 30 minutes beforehand. Samples were then centrifuged at maximum speed for 10 minutes at °C to remove protein debris, and supernatants were stored at -80°C until acquisition. Liquid chromatography-mass spectrometry (LC-MS) was carried out using an Agilent 1290 Infinity II UHPLC in line with a Bruker Impact II QTOF operating in negative ion mode, as previously described (Edwards-Hicks et al., 2020). LC separation was performed on a Phenomenex Luna propylamine column (50 x 2 mm, 3 μm particles) using a solvent gradient of 100% buffer B (5 mM ammonium carbonate in 90% acetonitrile) to 90% buffer A (10 mM NH4 in water). Flow rate was from 1000 to 750 μL/min. Autosampler temperature was 5°C, and injection volume was 2 μL. Metabolites were quantified using AssayR (Wills et al., 2017). The hierarchical clustering heatmap was generated in MetaboAnalyst 5.0 using Euclidean distance measure, the Ward clustering algorithm, and autoscale feature standardization (Pang et al., 2021).
Metabolic flux measurements were carried out with the Seahorse XFp Glycolytic Rate Assay and Cell Mito Stress Test kits (Agilent) according to the manufacturer’s instructions. On the day of the assay, 4 x 104 differentiated THP-1 macrophages were seeded per well of the XFp cartridge, allowed to adhere for 2 hours in a 37°C, 5% CO2 incubator, and then incubated with assay medium (XF DMEM medium with 10 mM glucose and 2 mM glutamine but without sodium pyruvate (Agilent)) for 45 − 60 minutes in a non- CO2 37°C incubator prior to data acquisition in a Seahorse XFp analyzer (Agilent).
Quantification and statistical analyses
Statistical analyses were performed on Prism (GraphPad) with each statistical test, definitions of center (mean or median) and dispersion (standard error of the mean), and the number of samples per group (n, referring to animals, individual cells, or pools of cells in a tissue culture well) indicated in the corresponding figure legends and panels. The unpaired, two-tailed Student’s t test was used to determine statistical significance between the mean values of two groups. One- or two-way Analysis of Variance (ANOVA) with Tukey’s or Sidak’s post tests were used to compare the mean values of three or more groups. Fisher’s exact test was used to analyze contingency table data (i.e., number of animals with mycobacterial cording vs. no cording). Statistical significance was determined by P < 0.05. Statistically significant comparisons in each figure are indicated with asterisks, ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001.
Acknowledgments
We thank M. Behr, P. Edelstein, M. Murphy, and F. Roca for discussions; M. Eisenberg-Bord and N. Yamaguchi for manuscript review; K. Takaki for parabiosis instruction; C. Hale for providing access to Seahorse XFp analyzer and advice on experimental design; J. Ray for assistance mapping mtorfh178; R. Berg, L. Hernández, S. Levitte, and J. Zimmermann for assistance with early characterization of mtorfh178; H. Boyd, B. Brockley, C. Dooley, S. McGuinan, R. Santhakumar, I. Smallwood, and R. White for technical and logistical assistance with genetic screens; J. Cameron, N. Goodwin, R. Foster, and the University of Cambridge aquatics facility staff for zebrafish husbandry; the LMB’s flow cytometry core facility and the NIHR Cambridge BRC Cell Phenotyping Hub for equipment access, and the LMB’s media service for preparation of bacterial and tissue culture reagents. This work was supported by the National Institutes of Health (T32-AI055396 to A.J.P. and MERIT award R37-AI054503 and Director’s Pioneer Award DP1MH099901 to L.R.), a Wellcome Trust Principal Research Fellowship (223103/Z/21/Z, L.R.), the Max Planck Society (E.L.P.), and the Liebnietz Prize (E.L.P).
Author contributions
A.J.P., C.B.M., D.M.T., and L.R. conceived the project. A.J.P., L.J.L., and L.R. designed experiments and analyzed data. A.J.P. and L.J.L. performed all experiments except the LC-MS metabolite profiling experiments, which were performed and analyzed by J.E.-H. D.M.T. isolated and mapped mtorfh178. C.B.M. and E.M.B.-N. provided mutagenized zebrafish lines. E.L.P. suggested the metabolite profiling experiments and advised on the design and interpretation of all metabolic experiments. A.J.P. and L.R. wrote the manuscript and got input from the other authors.
Declaration of interests
L.R. and E.L.P. are advisory board members for Cell. E.L.P. is a scientific advisory board member of ImmunoMet and a founder of Rheos Medicines. For the purpose of open access, the authors have applied for a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. This work is licensed under a Creative Commons Attribution 4.0 International License.
Published: September 13, 2022
Footnotes
Supplemental information can be found online at https://doi.org/10.1016/j.cell.2022.08.018.
Contributor Information
Antonio J. Pagán, Email: apagan@mrc-lmb.cam.ac.uk.
Lalita Ramakrishnan, Email: lalitar@mrc-lmb.cam.ac.uk.
Supplemental information
References
- Amaral E.P., Costa D.L., Namasivayam S., Riteau N., Kamenyeva O., Mittereder L., Mayer-Barber K.D., Andrade B.B., Sher A. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. J. Exp. Med. 2019;216:556–570. doi: 10.1084/jem.20181776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Armstrong J.A., Hart P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J. Exp. Med. 1971;134:713–740. doi: 10.1084/jem.134.3.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Augenstreich J., Arbues A., Simeone R., Haanappel E., Wegener A., Sayes F., Le Chevalier F., Chalut C., Malaga W., Guilhot C., et al. ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell. Microbiol. 2017;19:e12726. doi: 10.1111/cmi.12726. [DOI] [PubMed] [Google Scholar]
- Bao Y., Wang L., Sun J. A small protein but with diverse roles: a review of EsxA in mycobacterium-host interaction. Cells. 2021;10:1645. doi: 10.3390/cells10071645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barker L.P., George K.M., Falkow S., Small P.L. Differential trafficking of live and dead Mycobacterium marinum organisms in macrophages. Infect. Immun. 1997;65:1497–1504. doi: 10.1128/iai.65.4.1497-1504.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Battaglioni S., Benjamin D., Wälchli M., Maier T., Hall M.N. mTOR substrate phosphorylation in growth control. Cell. 2022;185:1814–1836. doi: 10.1016/j.cell.2022.04.013. [DOI] [PubMed] [Google Scholar]
- Beckwith K.S., Beckwith M.S., Ullmann S., Sætra R.S., Kim H., Marstad A., Åsberg S.E., Strand T.A., Haug M., Niederweis M., et al. Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infection. Nat. Commun. 2020;11:2270. doi: 10.1038/s41467-020-16143-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Behar S.M., Divangahi M., Remold H.G. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat. Rev. Microbiol. 2010;8:668–674. doi: 10.1038/nrmicro2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Behr M.A., Edelstein P.H., Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738. doi: 10.1136/bmj.k2738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Behr M.A., Edelstein P.H., Ramakrishnan L. Is Mycobacterium tuberculosis infection life long? BMJ. 2019;367:l5770. doi: 10.1136/bmj.l5770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bendall L.J., Green D.R. Autopsy of a cell. Leukemia. 2014;28:1341–1343. doi: 10.1038/leu.2014.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011;10:868–880. doi: 10.1038/nrd3531. [DOI] [PubMed] [Google Scholar]
- Bento C.F., Renna M., Ghislat G., Puri C., Ashkenazi A., Vicinanza M., Menzies F.M., Rubinsztein D.C. Mammalian autophagy: how does it work? Annu. Rev. Biochem. 2016;85:685–713. doi: 10.1146/annurev-biochem-060815-014556. [DOI] [PubMed] [Google Scholar]
- Berg R.D., Levitte S., O'Sullivan M.P., O'Leary S.M., Cambier C.J., Cameron J., Takaki K.K., Moens C.B., Tobin D.M., Keane J., et al. Lysosomal disorders drive susceptibility to tuberculosis by compromising macrophage migration. Cell. 2016;165:139–152. doi: 10.1016/j.cell.2016.02.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berthet F.X., Lagranderie M., Gounon P., Laurent-winter C., Ensergueix D., Chavarot P., Thouron F., Maranghi E., Pelicic V., Portnoï D., et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 1998;282:759–762. doi: 10.1126/science.282.5389.759. [DOI] [PubMed] [Google Scholar]
- Bhatt K., Bhagavathula M., Verma S., Timmins G.S., Deretic V.P., Ellner J.J., Salgame P. Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. Dis. Model. Mech. 2021;14:dmm049018. doi: 10.1242/dmm.049018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Braverman J., Sogi K.M., Benjamin D., Nomura D.K., Stanley S.A. HIF-1alpha is an essential mediator of IFN-gamma-dependent immunity to Mycobacterium tuberculosis. J. Immunol. 2016;197:1287–1297. doi: 10.4049/jimmunol.1600266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brodin P., de Jonge M.I., Majlessi L., Leclerc C., Nilges M., Cole S.T., Brosch R. Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. J. Biol. Chem. 2005;280:33953–33959. doi: 10.1074/jbc.M503515200. [DOI] [PubMed] [Google Scholar]
- Burger A., Lindsay H., Felker A., Hess C., Anders C., Chiavacci E., Zaugg J., Weber L.M., Catena R., Jinek M., et al. Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes. Development. 2016;143:2025–2037. doi: 10.1242/dev.134809. [DOI] [PubMed] [Google Scholar]
- Cambier C.J., Falkow S., Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell. 2014;159:1497–1509. doi: 10.1016/j.cell.2014.11.024. [DOI] [PubMed] [Google Scholar]
- Cambier C.J., Takaki K.K., Larson R.P., Hernandez R.E., Tobin D.M., Urdahl K.B., Cosma C.L., Ramakrishnan L. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature. 2014;505:218–222. doi: 10.1038/nature12799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Canetti G., Sutherland I., Svandova E. Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis. Bull. Int. Union Tuberc. 1972;47:116–134. [PubMed] [Google Scholar]
- Champion M.M., Williams E.A., Pinapati R.S., Champion P.A. Correlation of phenotypic profiles using targeted proteomics identifies mycobacterial esx-1 substrates. J. Proteome Res. 2014;13:5151–5164. doi: 10.1021/pr500484w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen M., Divangahi M., Gan H., Shin D.S., Hong S., Lee D.M., Serhan C.N., Behar S.M., Remold H.G. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J. Exp. Med. 2008;205:2791–2801. doi: 10.1084/jem.20080767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clay H., Volkman H.E., Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity. 2008;29:283–294. doi: 10.1016/j.immuni.2008.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clemens D.L., Horwitz M.A. Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited. J. Exp. Med. 1995;181:257–270. doi: 10.1084/jem.181.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Clements W.K., Traver D. Signalling pathways that control vertebrate haematopoietic stem cell specification. Nat. Rev. Immunol. 2013;13:336–348. doi: 10.1038/nri3443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Conrad W.H., Osman M.M., Shanahan J.K., Chu F., Takaki K.K., Cameron J., Hopkinson-Woolley D., Brosch R., Ramakrishnan L. Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions. Proc. Natl. Acad. Sci. USA. 2017;114:1371–1376. doi: 10.1073/pnas.1620133114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cosma C.L., Klein K., Kim R., Beery D., Ramakrishnan L. Mycobacterium marinum Erp is a virulence determinant required for cell wall integrity and intracellular survival. Infect. Immun. 2006;74:3125–3133. doi: 10.1128/IAI.02061-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cosma C.L., Sherman D.R., Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu. Rev. Microbiol. 2003;57:641–676. doi: 10.1146/annurev.micro.57.030502.091033. [DOI] [PubMed] [Google Scholar]
- Cumming B.M., Addicott K.W., Adamson J.H., Steyn A.J. Mycobacterium tuberculosis induces decelerated bioenergetic metabolism in human macrophages. eLife. 2018;7:e39169. doi: 10.7554/eLife.39169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cunningham J.T., Rodgers J.T., Arlow D.H., Vazquez F., Mootha V.K., Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450:736–740. doi: 10.1038/nature06322. [DOI] [PubMed] [Google Scholar]
- Davis J.M., Clay H., Lewis J.L., Ghori N., Herbomel P., Ramakrishnan L. Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity. 2002;17:693–702. doi: 10.1016/s1074-7613(02)00475-2. [DOI] [PubMed] [Google Scholar]
- Davis J.M., Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell. 2009;136:37–49. doi: 10.1016/j.cell.2008.11.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Decout A., Katz J.D., Venkatraman S., Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021;21:548–569. doi: 10.1038/s41577-021-00524-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Demy D.L., Ranta Z., Giorgi J.M., Gonzalez M., Herbomel P., Kissa K. Generating parabiotic zebrafish embryos for cell migration and homing studies. Nat. Methods. 2013;10:256–258. doi: 10.1038/nmeth.2362. [DOI] [PubMed] [Google Scholar]
- Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., Fortune S., Behar S.M., Remold H.G. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 2009;10:899–906. doi: 10.1038/ni.1758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell. 2010;39:171–183. doi: 10.1016/j.molcel.2010.06.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edwards-Hicks J., Mitterer M., Pearce E.L., Buescher J.M. Metabolic dynamics of in vitro CD8+ T cell activation. Metabolites. 2020;11 doi: 10.3390/metabo11010012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Feldman W.H., Baggenstoss A.H. The reisdual infectivity of the primary complex of tuberculosis. Am. J. Pathol. 1938;14:473–490.3. [PMC free article] [PubMed] [Google Scholar]
- Fijałkowska-Morawska J.B., Jagodzińska M., Nowicki M. Pulmonary embolism and reactivation of tuberculosis during everolimus therapy in a kidney transplant recipient. Ann. Transplant. 2011;16:107–110. doi: 10.12659/aot.882226. [DOI] [PubMed] [Google Scholar]
- Fine-Coulson K., Giguère S., Quinn F.D., Reaves B.J. Infection of A549 human type II epithelial cells with Mycobacterium tuberculosis induces changes in mitochondrial morphology, distribution and mass that are dependent on the early secreted antigen, ESAT-6. Microbes Infect. 2015;17:689–697. doi: 10.1016/j.micinf.2015.06.003. [DOI] [PubMed] [Google Scholar]
- Formosa L.E., Dibley M.G., Stroud D.A., Ryan M.T. Building a complex complex: assembly of mitochondrial respiratory chain complex I. Semin. Cell Dev. Biol. 2018;76:154–162. doi: 10.1016/j.semcdb.2017.08.011. [DOI] [PubMed] [Google Scholar]
- Fortune S.M., Jaeger A., Sarracino D.A., Chase M.R., Sassetti C.M., Sherman D.R., Bloom B.R., Rubin E.J. Mutually dependent secretion of proteins required for mycobacterial virulence. Proc. Natl. Acad. Sci. USA. 2005;102:10676–10681. doi: 10.1073/pnas.0504922102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Galluzzi L., Bravo-San Pedro J.M., Kepp O., Kroemer G. Regulated cell death and adaptive stress responses. Cell. Mol. Life Sci. 2016;73:2405–2410. doi: 10.1007/s00018-016-2209-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Garcia C.A., Wu S. Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer. Cancer Investig. 2016;34:521–530. doi: 10.1080/07357907.2016.1242009. [DOI] [PubMed] [Google Scholar]
- Garritano S., Gemignani F., Voegele C., Nguyen-Dumont T., Le Calvez-Kelm F., De Silva D., Lesueur F., Landi S., Tavtigian S.V. Determining the effectiveness of high resolution melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet. 2009;10:5. doi: 10.1186/1471-2156-10-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gleeson L.E., Sheedy F.J., Palsson-McDermott E.M., Triglia D., O'Leary S.M., O'Sullivan M.P., O'Neill L.A., Keane J. Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J. Immunol. 2016;196:2444–2449. doi: 10.4049/jimmunol.1501612. [DOI] [PubMed] [Google Scholar]
- González A., Hall M.N., Lin S.C., Hardie D.G. AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31:472–492. doi: 10.1016/j.cmet.2020.01.015. [DOI] [PubMed] [Google Scholar]
- Gottlieb E., Armour S.M., Harris M.H., Thompson C.B. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003;10:709–717. doi: 10.1038/sj.cdd.4401231. [DOI] [PubMed] [Google Scholar]
- Green D.R., Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157:65–75. doi: 10.1016/j.cell.2014.02.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gröschel M.I., Sayes F., Simeone R., Majlessi L., Brosch R. ESX secretion systems: mycobacterial evolution to counter host immunity. Nat. Rev. Microbiol. 2016;14:677–691. doi: 10.1038/nrmicro.2016.131. [DOI] [PubMed] [Google Scholar]
- Halestrap A.P. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem. J. 1975;148:85–96. doi: 10.1042/bj1480085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hall C., Flores M.V., Storm T., Crosier K., Crosier P. The zebrafish lysozyme C promoter drives myeloid-specific expression in transgenic fish. BMC Dev. Biol. 2007;7:42. doi: 10.1186/1471-213X-7-42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harris J., Hope J.C., Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J. Infect. Dis. 2008;198:1842–1850. doi: 10.1086/593174. [DOI] [PubMed] [Google Scholar]
- He C., Bartholomew C.R., Zhou W., Klionsky D.J. Assaying autophagic activity in transgenic GFP-Lc3 and GFP-Gabarap zebrafish embryos. Autophagy. 2009;5:520–526. doi: 10.4161/auto.5.4.7768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- He C., Holme J., Anthony J. SNP genotyping: the KASP assay. Methods Mol. Biol. 2014;1145:75–86. doi: 10.1007/978-1-4939-0446-4_7. [DOI] [PubMed] [Google Scholar]
- Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., Germain G.S., Abraham R.T., Houghton P.J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59:886–894. [PubMed] [Google Scholar]
- Huang L., Nazarova E.V., Tan S., Liu Y., Russell D.G. Growth of Mycobacterium tuberculosis in vivo segregates with host macrophage metabolism and ontogeny. J. Exp. Med. 2018;215:1135–1152. doi: 10.1084/jem.20172020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jamwal S., Midha M.K., Verma H.N., Basu A., Rao K.V., Manivel V. Characterizing virulence-specific perturbations in the mitochondrial function of macrophages infected with Mycobacterium tuberculosis. Sci. Rep. 2013;3:1328. doi: 10.1038/srep01328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jeon S.Y., Yhim H.Y., Lee N.R., Song E.K., Kwak J.Y., Yim C.Y. Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma. Korean J. Intern. Med. 2017;32:365–368. doi: 10.3904/kjim.2015.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karmaus P.W.F., Herrada A.A., Guy C., Neale G., Dhungana Y., Long L., Vogel P., Avila J., Clish C.B., Chi H. Critical roles of mTORC1 signaling and metabolic reprogramming for M-CSF-mediated myelopoiesis. J. Exp. Med. 2017;214:2629–2647. doi: 10.1084/jem.20161855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kettleborough R.N., Busch-Nentwich E.M., Harvey S.A., Dooley C.M., de Bruijn E., van Eeden F., Sealy I., White R.J., Herd C., Nijman I.J., et al. A systematic genome-wide analysis of zebrafish protein-coding gene function. Nature. 2013;496:494–497. doi: 10.1038/nature11992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khattak S., Murawala P., Andreas H., Kappert V., Schuez M., Sandoval-Guzmán T., Crawford K., Tanaka E.M. Optimized axolotl (Ambystoma mexicanum) husbandry, breeding, metamorphosis, transgenesis and tamoxifen-mediated recombination. Nat. Protoc. 2014;9:529–540. doi: 10.1038/nprot.2014.040. [DOI] [PubMed] [Google Scholar]
- Kozik P., Gros M., Itzhak D.N., Joannas L., Heurtebise-Chrétien S., Krawczyk P.A., Rodríguez-Silvestre P., Alloatti A., Magalhaes J.G., Del Nery E., et al. Small molecule enhancers of endosome-to-cytosol import augment anti-tumor immunity. Cell Rep. 2020;32:107905. doi: 10.1016/j.celrep.2020.107905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lachmandas E., Beigier-Bompadre M., Cheng S.C., Kumar V., van Laarhoven A., Wang X., Ammerdorffer A., Boutens L., de Jong D., Kanneganti T.D., et al. Rewiring cellular metabolism via the AKT/mTOR pathway contributes to host defence against Mycobacterium tuberculosis in human and murine cells. Eur. J. Immunol. 2016;46:2574–2586. doi: 10.1002/eji.201546259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee J., Repasy T., Papavinasasundaram K., Sassetti C., Kornfeld H. Mycobacterium tuberculosis induces an atypical cell death mode to escape from infected macrophages. PLoS One. 2011;6:e18367. doi: 10.1371/journal.pone.0018367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee P.Y., Sykes D.B., Ameri S., Kalaitzidis D., Charles J.F., Nelson-Maney N., Wei K., Cunin P., Morris A., Cardona A.E., et al. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Sci. Immunol. 2017;2:eaam6641. doi: 10.1126/sciimmunol.aam6641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lerner T.R., Queval C.J., Fearns A., Repnik U., Griffiths G., Gutierrez M.G. Phthiocerol dimycocerosates promote access to the cytosol and intracellular burden of Mycobacterium tuberculosis in lymphatic endothelial cells. BMC Biol. 2018;16:1. doi: 10.1186/s12915-017-0471-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levitte S., Adams K.N., Berg R.D., Cosma C.L., Urdahl K.B., Ramakrishnan L. Mycobacterial acid tolerance enables phagolysosomal survival and establishment of tuberculous infection in vivo. Cell Host Microbe. 2016;20:250–258. doi: 10.1016/j.chom.2016.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lienard J., Nobs E., Lovins V., Movert E., Valfridsson C., Carlsson F. The Mycobacterium marinum ESX-1 system mediates phagosomal permeabilization and type I interferon production via separable mechanisms. Proc. Natl. Acad. Sci. USA. 2020;117:1160–1166. doi: 10.1073/pnas.1911646117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lin H.F., Traver D., Zhu H., Dooley K., Paw B.H., Zon L.I., Handin R.I. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood. 2005;106:3803–3810. doi: 10.1182/blood-2005-01-0179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liu G.Y., Sabatini D.M. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 2020;21:183–203. doi: 10.1038/s41580-019-0199-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ma D., Zhang J., Lin H.F., Italiano J., Handin R.I. The identification and characterization of zebrafish hematopoietic stem cells. Blood. 2011;118:289–297. doi: 10.1182/blood-2010-12-327403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mannick J.B., Del Giudice G., Lattanzi M., Valiante N.M., Praestgaard J., Huang B., Lonetto M.A., Maecker H.T., Kovarik J., Carson S., et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 2014;6:268ra179. doi: 10.1126/scitranslmed.3009892. [DOI] [PubMed] [Google Scholar]
- Mannick J.B., Morris M., Hockey H.P., Roma G., Beibel M., Kulmatycki K., Watkins M., Shavlakadze T., Zhou W., Quinn D., et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. 2018;10:eaaq1564. doi: 10.1126/scitranslmed.aaq1564. [DOI] [PubMed] [Google Scholar]
- Matty M.A., Knudsen D.R., Walton E.M., Beerman R.W., Cronan M.R., Pyle C.J., Hernandez R.E., Tobin D.M. Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection. eLife. 2019;8:e39123. doi: 10.7554/eLife.39123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mohareer K., Medikonda J., Vadankula G.R., Banerjee S. Mycobacterial control of host mitochondria: bioenergetic and metabolic changes shaping cell fate and infection outcome. Front. Cell. Infect. Microbiol. 2020;10:457. doi: 10.3389/fcimb.2020.00457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morita M., Gravel S.P., Chénard V., Sikström K., Zheng L., Alain T., Gandin V., Avizonis D., Arguello M., Zakaria C., et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18:698–711. doi: 10.1016/j.cmet.2013.10.001. [DOI] [PubMed] [Google Scholar]
- Morita M., Prudent J., Basu K., Goyon V., Katsumura S., Hulea L., Pearl D., Siddiqui N., Strack S., McGuirk S., et al. mTOR controls mitochondrial dynamics and cell survival via MTFP1. Mol. Cell. 2017;67:922–935.e5. doi: 10.1016/j.molcel.2017.08.013. [DOI] [PubMed] [Google Scholar]
- Mosimann C., Kaufman C.K., Li P., Pugach E.K., Tamplin O.J., Zon L.I. Ubiquitous transgene expression and Cre-based recombination driven by the ubiquitin promoter in zebrafish. Development. 2011;138:169–177. doi: 10.1242/dev.059345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mouton J.M., Heunis T., Dippenaar A., Gallant J.L., Kleynhans L., Sampson S.L. Comprehensive characterization of the attenuated double auxotroph mycobacterium tuberculosisDeltaleuDDeltapanCD as an alternative to H37Rv. Front. Microbiol. 2019;10:1922. doi: 10.3389/fmicb.2019.01922. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009;417:1–13. doi: 10.1042/BJ20081386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muthukkumar S., Ramesh T.M., Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264–270. doi: 10.1097/00007890-199508000-00010. [DOI] [PubMed] [Google Scholar]
- Olson G.S., Murray T.A., Jahn A.N., Mai D., Diercks A.H., Gold E.S., Aderem A. Type I interferon decreases macrophage energy metabolism during mycobacterial infection. Cell Rep. 2021;35:109195. doi: 10.1016/j.celrep.2021.109195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Neill L.A., Pearce E.J. Immunometabolism governs dendritic cell and macrophage function. J. Exp. Med. 2016;213:15–23. doi: 10.1084/jem.20151570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ong C.W., Elkington P.T., Friedland J.S. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 2014;190:9–18. doi: 10.1164/rccm.201311-2106PP. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Opie E.L., Aronson J.D. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch. Pathol. Lab. Med. 1927;4:1–21. [Google Scholar]
- Osman M.M., Pagán A.J., Shanahan J.K., Ramakrishnan L. Mycobacterium marinum phthiocerol dimycocerosates enhance macrophage phagosomal permeabilization and membrane damage. PLoS One. 2020;15:e0233252. doi: 10.1371/journal.pone.0233252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Osman M.M., Shanahan J.K., Chu F., Takaki K.K., Pinckert M.L., Pagán A.J., Brosch R., Conrad W.H., Ramakrishnan L. The C terminus of the mycobacterium ESX-1 secretion system substrate ESAT-6 is required for phagosomal membrane damage and virulence. Proc. Natl. Acad. Sci. USA. 2022;119 doi: 10.1073/pnas.2122161119. e2122161119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pagán A.J., Ramakrishnan L. Immunity and immunopathology in the tuberculous granuloma. Cold Spring Harbor Perspect. Med. 2014;5:a018499. doi: 10.1101/cshperspect.a018499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pagán A.J., Ramakrishnan L. The formation and function of granulomas. Annu. Rev. Immunol. 2018;36:639–665. doi: 10.1146/annurev-immunol-032712-100022. [DOI] [PubMed] [Google Scholar]
- Pagán A.J., Yang C.T., Cameron J., Swaim L.E., Ellett F., Lieschke G.J., Ramakrishnan L. Myeloid growth factors promote resistance to mycobacterial infection by curtailing granuloma necrosis through macrophage replenishment. Cell Host Microbe. 2015;18:15–26. doi: 10.1016/j.chom.2015.06.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pajuelo D., Gonzalez-Juarbe N., Tak U., Sun J., Orihuela C.J., Niederweis M. NAD(+) depletion triggers macrophage necroptosis, a cell death pathway exploited by Mycobacterium tuberculosis. Cell Rep. 2018;24:429–440. doi: 10.1016/j.celrep.2018.06.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pang Z., Chong J., Zhou G., de Lima Morais D.A., Chang L., Barrette M., Gauthier C., Jacques P.É., Li S., Xia J. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49:W388–W396. doi: 10.1093/nar/gkab382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Papadopoli D., Boulay K., Kazak L., Pollak M., Mallette F., Topisirovic I., Hulea L. mTOR as a central regulator of lifespan and aging. F1000Res. 2019;8:8. doi: 10.12688/f1000research.17196.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patra K.C., Hay N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 2014;39:347–354. doi: 10.1016/j.tibs.2014.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paulson T. Epidemiology: A mortal foe. Nature. 2013;502:S2–S3. doi: 10.1038/502S2a. [DOI] [PubMed] [Google Scholar]
- Pernas L. Cellular metabolism in the defense against microbes. J. Cell Sci. 2021;134:jcs252023. doi: 10.1242/jcs.252023. [DOI] [PubMed] [Google Scholar]
- Powell J.D., Pollizzi K.N., Heikamp E.B., Horton M.R. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 2012;30:39–68. doi: 10.1146/annurev-immunol-020711-075024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Quigley J., Hughitt V.K., Velikovsky C.A., Mariuzza R.A., El-Sayed N.M., Briken V. The cell wall lipid PDIM contributes to phagosomal escape and host cell exit of Mycobacterium tuberculosis. mBio. 2017;8 doi: 10.1128/mBio.00148-17. e00148–e00117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 2012;12:352–366. doi: 10.1038/nri3211. [DOI] [PubMed] [Google Scholar]
- Ramakrishnan L. The zebrafish guide to tuberculosis immunity and treatment. Cold Spring Harb. Symp. Quant. Biol. 2013;78:179–192. doi: 10.1101/sqb.2013.78.023283. [DOI] [PubMed] [Google Scholar]
- Ramakrishnan L. Mycobacterium tuberculosis pathogenicity viewed through the lens of molecular Koch's postulates. Curr. Opin. Microbiol. 2020;54:103–110. doi: 10.1016/j.mib.2020.01.011. [DOI] [PubMed] [Google Scholar]
- Rambold A.S., Pearce E.L. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 2018;39:6–18. doi: 10.1016/j.it.2017.08.006. [DOI] [PubMed] [Google Scholar]
- Roca F.J., Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell. 2013;153:521–534. doi: 10.1016/j.cell.2013.03.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roca F.J., Whitworth L.J., Prag H.A., Murphy M.P., Ramakrishnan L. Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. Science. 2022;376 doi: 10.1126/science.abh2841. eabh2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roca F.J., Whitworth L.J., Redmond S., Jones A.A., Ramakrishnan L. TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit. Cell. 2019;178:1344–1361.e11. doi: 10.1016/j.cell.2019.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ruiz-Camps I., Aguilar-Company J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther. Adv. Infect. Dis. 2021;8 doi: 10.1177/2049936121989548. 2049936121989548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Russell D.G. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 2007;5:39–47. doi: 10.1038/nrmicro1538. [DOI] [PubMed] [Google Scholar]
- Ryan D.G., O'Neill L.A.J. Krebs cycle reborn in macrophage immunometabolism. Annu. Rev. Immunol. 2020;38:289–313. doi: 10.1146/annurev-immunol-081619-104850. [DOI] [PubMed] [Google Scholar]
- Sampson S.L., Dascher C.C., Sambandamurthy V.K., Russell R.G., Jacobs W.R., Jr., Bloom B.R., Hondalus M.K. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect. Immun. 2004;72:3031–3037. doi: 10.1128/IAI.72.5.3031-3037.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sampson S.L., Mansfield K.G., Carville A., Magee D.M., Quitugua T., Howerth E.W., Bloom B.R., Hondalus M.K. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine. 2011;29:4839–4847. doi: 10.1016/j.vaccine.2011.04.066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saxton R.A., Sabatini D.M. MTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976. doi: 10.1016/j.cell.2017.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schieke S.M., Phillips D., McCoy J.P., Jr., Aponte A.M., Shen R.F., Balaban R.S., Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem. 2006;281:27643–27652. doi: 10.1074/jbc.M603536200. [DOI] [PubMed] [Google Scholar]
- Shi L., Salamon H., Eugenin E.A., Pine R., Cooper A., Gennaro M.L. Infection with Mycobacterium tuberculosis induces the Warburg effect in mouse lungs. Sci. Rep. 2015;5:18176. doi: 10.1038/srep18176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simeone R., Bobard A., Lippmann J., Bitter W., Majlessi L., Brosch R., Enninga J. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog. 2012;8:e1002507. doi: 10.1371/journal.ppat.1002507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Simeone R., Sayes F., Lawarée E., Brosch R. Breaching the phagosome, the case of the tuberculosis agent. Cell. Microbiol. 2021;23:e13344. doi: 10.1111/cmi.13344. [DOI] [PubMed] [Google Scholar]
- Sinclair C., Bommakanti G., Gardinassi L., Loebbermann J., Johnson M.J., Hakimpour P., Hagan T., Benitez L., Todor A., Machiah D., et al. mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science. 2017;357:1014–1021. doi: 10.1126/science.aaj2155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Srinivasan L., Ahlbrand S., Briken V. Interaction of Mycobacterium tuberculosis with host cell death pathways. Cold Spring Harbor Perspect. Med. 2014;4:a022459. doi: 10.1101/cshperspect.a022459. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Suster M.L., Abe G., Schouw A., Kawakami K. Transposon-mediated BAC transgenesis in zebrafish. Nat. Protoc. 2011;6:1998–2021. doi: 10.1038/nprot.2011.416. [DOI] [PubMed] [Google Scholar]
- Swaim L.E., Connolly L.E., Volkman H.E., Humbert O., Born D.E., Ramakrishnan L. Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. Infect. Immun. 2006;74:6108–6117. doi: 10.1128/IAI.00887-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swanson K.V., Deng M., Ting J.P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477–489. doi: 10.1038/s41577-019-0165-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Takaki K., Davis J.M., Winglee K., Ramakrishnan L. Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat. Protoc. 2013;8:1114–1124. doi: 10.1038/nprot.2013.068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Terplan K. Pathogenesis of postprimary tuberculosis, in relation to chronic pulmonary tuberculosis (phtisis) Bibl. Tuberc. 1951;5:186–219. [PubMed] [Google Scholar]
- Thomas E.D., Cruz I.A., Hailey D.W., Raible D.W. There and back again: development and regeneration of the zebrafish lateral line system. Wiley Interdiscip. Rev. Dev. Biol. 2015;4:1–16. doi: 10.1002/wdev.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., Ko D.C., Zou Y., Bang N.D., Chau T.T., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012;148:434–446. doi: 10.1016/j.cell.2011.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tobin D.M., Vary J.C., Jr., Ray J.P., Walsh G.S., Dunstan S.J., Bang N.D., Hagge D.A., Khadge S., King M.C., Hawn T.R., et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell. 2010;140:717–730. doi: 10.1016/j.cell.2010.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT) BioTechniques. 2000;29:52. doi: 10.2144/00291bm09. 54. [DOI] [PubMed] [Google Scholar]
- Tsai M.K., Lee C.Y., Hu R.H., Lee P.H. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients. J. Formos. Med. Assoc. 2007;106:372–379. doi: 10.1016/S0929-6646(09)60322-3. [DOI] [PubMed] [Google Scholar]
- van Ham T.J., Mapes J., Kokel D., Peterson R.T. Live imaging of apoptotic cells in zebrafish. FASEB J. 2010;24:4336–4342. doi: 10.1096/fj.10-161018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vandal O.H., Pierini L.M., Schnappinger D., Nathan C.F., Ehrt S. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat. Med. 2008;14:849–854. doi: 10.1038/nm.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Volkman H.E., Clay H., Beery D., Chang J.C., Sherman D.R., Ramakrishnan L. Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol. 2004;2:e367. doi: 10.1371/journal.pbio.0020367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wallis R.S., Ginindza S., Beattie T., Arjun N., Likoti M., Edward V.A., Rassool M., Ahmed K., Fielding K., Ahidjo B.A., et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir. Med. 2021;9:897–908. doi: 10.1016/S2213-2600(20)30448-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walton E.M., Cronan M.R., Beerman R.W., Tobin D.M. The macrophage-specific promoter mfap4 allows live, long-term analysis of macrophage behavior during mycobacterial infection in zebrafish. PLoS One. 2015;10:e0138949. doi: 10.1371/journal.pone.0138949. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weichhart T., Hengstschläger M., Linke M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 2015;15:599–614. doi: 10.1038/nri3901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whitworth L., Coxon J., van Laarhoven A., Thuong N.T.T., Dian S., Alisjahbana B., Ganiem A.R., van Crevel R., Thwaites G.E., Troll M., et al. A Bayesian analysis of the association between leukotriene A4 hydrolase genotype and survival in tuberculous meningitis. eLife. 2021;10:e61722. doi: 10.7554/eLife.61722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whitworth L.J., Troll R., Pagán A.J., Roca F.J., Edelstein P.H., Troll M., Tobin D.M., Phu N.H., Bang N.D., Thwaites G.E., et al. Elevated cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response to dexamethasone. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2024852118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wiens K.E., Ernst J.D. The mechanism for Type I interferon induction by Mycobacterium tuberculosis is bacterial strain-dependent. PLoS Pathog. 2016;12:e1005809. doi: 10.1371/journal.ppat.1005809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wills J., Edwards-Hicks J., Finch A.J. AssayR: A simple mass spectrometry software tool for targeted metabolic and stable isotope tracer analyses. Anal. Chem. 2017;89:9616–9619. doi: 10.1021/acs.analchem.7b02401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wong Y.C., Ysselstein D., Krainc D. Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature. 2018;554:382–386. doi: 10.1038/nature25486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu R.S., Lam I.I., Clay H., Duong D.N., Deo R.C., Coughlin S.R. A rapid method for directed gene knockout for screening in G0 zebrafish. Dev. Cell. 2018;46:112–125.e4. doi: 10.1016/j.devcel.2018.06.003. [DOI] [PubMed] [Google Scholar]
- Zhang L., Jiang X., Pfau D., Ling Y., Nathan C.F. Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death. J. Exp. Med. 2021;218 doi: 10.1084/jem.20200887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang Q., Wang D., Jiang G., Liu W., Deng Q., Li X., Qian W., Ouellet H., Sun J. EsxA membrane-permeabilizing activity plays a key role in mycobacterial cytosolic translocation and virulence: effects of single-residue mutations at glutamine 5. Sci. Rep. 2016;6:32618. doi: 10.1038/srep32618. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
-
•
Microscopy and flow cytometry data reported in this paper will be shared by the lead contact upon request. The unprocessed metabolomics data generated in this study are available from the lead contact.
-
•
This paper does not report original code.
-
•
Any additional information needed to reanalyze the data reported in this paper is available from the lead contact upon request.